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ABSTRACT
THE SECOND GENERATION OF CCCM SYSTEM FOR IN-VITRO
CARDIAC TISSUE ENGINEERING
Mai Dung Thi Nguyen
June 17, 2014
Cardiovascular disease is the leading cause of death worldwide. When a myocardial
infarction occurs, scar tissue compensates the damaged myocardial tissue. This scar
tissue increases the stiffness of the heart tissue, reduces the heart’s function, and finally
leads to the heart failure (HF) disease. To have the tissue engraftment, in-vitro cardiac
tissue should have the same properties as the native mature cardiac tissue. However,
current in-vitro cell culture technologies fail to accurately recreate the in-vivo like
mechanically physiological environment for in-vitro cardiac tissue culture, and therefore,
fail to regenerate the in-vivo like mature cardiac tissue. Hence, a microfluidic cardiac cell
culture model (CCCM) system was developed to better recreate the cellular environment
and advance cardiac regeneration. CCCM system replicates the hemodynamic loading
and unloading conditions occurring inside the left ventricle of a heart. With this system,
different pressures of human heart conditions may be replicated for a variety of clinical
and physiologic conditions.

For proof-of-concept, embryonic chick cardiac cells with

normal heart condition were applied.

Compared to the tissue cultured in a static

condition, tissues stimulated in the CCCM system achieved an in-vivo like cardiac

vi

matured phenotype, had higher proliferating rate, showed more maturity, and expressed
more contractile proteins. These results demonstrated that the CCCM system can be used
to study the behavior of cardiomyocytes in different mechanical heart conditions and to
create mature cardiac tissue which will benefit cardiac tissue transplant for HF.
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CHAPTER 1
INTRODUCTION

1.1. CARDIOVASCULAR DISEASE (CVD)
The basic components of the cardiovascular system are the heart, blood vessels (arteries,
capillaries, and veins), autonomic innervation of the heart and vasculature, and the
circulating blood. The heart acts as a pump to circulate blood through the lungs to
oxygenate, and through the arteries to deliver oxygen and nutrients to the entire body.
When blood is delivered to tissues, the oxygen and carbon dioxide are exchanged. The
deoxygenated blood is then returned to the heart via veins, and finally to the lungs,
helping dispose of carbon dioxide and other waste products.

Cardiovascular Disease (CVD) collectively refers to abnormalities associated with
various components of the cardiovascular system and covers over 60 disorders relating to
the heart and vascular system. CVD is the leading cause of death in the United States,
which is higher than the next four leading causes of death combined. 1 Statistics from the
American Heart Associate (AHA) indicate that about 81 million people or 1/4 th of the
population suffer from some form of CVD in the United States. This includes high blood
pressure ~ 74.5 million; coronary heart disease ~ 17.6 million; stroke ~ 6.4 million;
congenital cardiovascular defects ~ 650,000 to 1.3 million; and heart failure ~ 5.8
million.2 Based on the article: “Heart Disease and Stroke 2010 Update” from AHA, it
1

was estimated that the total indirect and direct cost due to CVD and stroke in 2010 would
be ~ 503.2 billion dollars, placing a severe burden on the economy and diminishing the
quality of life for several thousands of people.2-4

CVD can be classified into two major categories based on disorders of the heart or the
vascular system. Disorders of the heart include conditions such as angina pectoris,
arrhythmias, cardiomyopathy, congestive heart failure, and congenital heart disease.
Disorders of the vascular system, on the other hand, include conditions such as aortic
aneurysms, arteriosclerosis, high blood pressure, stroke, and transient ischemia. 1,

5

Coronary heart disease is the most common type of CVD. It is a condition which fatty
deposits build up inside the inner walls of coronary arteries, creating blockages of the
arteries. These blockages reduce the blood flow, causing a pain or discomfort in the
chest, heart failure (HF) and heart attacks. In atherosclerosis,, the arteries become thicker
or harden; and the inner wall of the arteries becomes narrower due to the deposits of fat,
cholesterol or other substances. This narrowed passage can block the blood flow and
lead to heart attacks and strokes. Strokes occur when the blood vessels to the brain are
occluded or broken. As a result, brain cells begin to die due to lack of oxygen and
nutrition.2-4 Stroke usually relates closely to high blood pressure, which happens when
the pressure inside the vessels is higher than the normal range, which is about 120/80
mmHg.

High blood pressure can cause HF, stroke, kidney failure, or other health

problems. The end stage for different CVDs is HF (Fig.1.1) which occurs when the heart
fails to pump sufficient blood through the body. The body, therefore, does not get
enough oxygen and nutrients. HF may develop slowly over time, and if not treated, can

2

cause life-threatening conditions, including pulmonary edema, failure of brain, kidney
and other major organs, and myocardial infarction.6-9

Figure 1.1: Heart Failure is the end-stage of dysfunctional cardiovascular system existing
for a long term.

1.2. TREATMENT OF HEART FAILURE
Heart Failure (HF) is a chronic disease, therefore, the treatment for HF needs lifelong
management, which includes changes in living habits, medication, and assist devices to
augment heart function.

7, 10, 11

The only cure for end- stage heart failure is total heart

transplantation.

Drug therapy is usually used for the initial stage of the HF. Depending on the stage and
symptoms of HF, a single or combination of different medications are applied. The most
common drugs used for treatment of HF include Angiotensin-converting enzyme
inhibitors, or Angiotensin II receptor blockers, Digoxin (Lanoxin), Beta blockers,
Diuretics, and Aldosterone antagonists.12 Angiotensin-converting enzyme inhibitors or
3

Angiotensin II receptor blockers dilate the arteries and improve blood flow, therefore,
decrease the workload on the heart. Digoxin helps to strengthen the contraction of heart
muscle and slow the heartbeat.

Beta blockers reduce the heart rate and pressure.

Diuretics enhance urination frequency to keep from the fluid building up in the body,
especially in the lungs. Aldosterone antagonists help the heart work better.

When the HF advances to a more serious stage, devices that optimize myocardial
function may be used for the treatment.

For example, implantable cardioverter-

defibrillators are used for monitoring the heart rhythm.

Cardiac resynchronization

therapy, or biventricular pacing, are used to help the heart pump efficiently by sending
timed electrical impulses to the heart's ventricles for contraction. Mechanical circulatory
support devices (left ventricular assist devices (LVAD) ) that unload the native ventricle
are used as a bridge to transplantation or as destination therapy in patients with severe HF
that are refractory to medical therapy.13 LVADs are mechanical pumps designed to
transport blood from the left ventricle through the body.

Heart transplant is a palliative therapy used for a subset of pediatric and adult patients
with progressive and irreversible HF. A healthier heart from a donor is replaced for the
failing diseased heart.14 However, people undergoing heart transplant face high risks of
the rejection of the donor heart, infection, artery problems, medication side effects and
the potential high risk of cancer due to the immune-suppressant medications.14

In

addition, due to the shortage of donors, people who need heart transplants experience a
long waiting times. Heart transplant or LVAD are currently the only options for the end-

4

stage HF. However, due to the lack of donors and the complications associated with
immunosuppressive treatments as well as many high risks occurred during surgery,
scientists and surgeons continue to search for new strategies to treat the HF.

1.3. THE HEART
1.3.1. Overview of the formation of the heart in the embryo
The heart is one of the first functioning organs formed during the embryonic period, both
in bird and mammalian embryos.15, 16 The heart derives from the anterior mesoderm, the
middle embryonic layer. First, one group of the mesodermal cells differentiate into
precardiac cells, which later transform into myocardial, endothelial and smooth muscle
cells. These mesodermal precardiac cells migrate and form the primitive linear heart
tube, which includes the inner endothelial, cardiac jelly, and external myocardial layers.
Another population of cardiac cells differentiates into cardiac myocytes, smooth muscle
cells, and endothelial cells.17, 18 Then, the primitive straight heart tube loops and folds
into an S-shape, followed by the convergence process. During this convergence phase,
the formation of trabeculae begins; and hemodynamic stimulation plays an important role
in modulating the trabecular patterning and development.19 The heart surface area,
myocardial mass and wall stiffness increase as a result of this trabecular formation. At
the end of this formation, the trabecular compaction begins, which contributes to the
formation of ventricular septum and the thickness of the ventricular compact layer. At
this time, the separation between the atria and ventricles, via the inlet segment, occurs
and the formation of atria and ventricle develops.17, 20 Following the convergence is the
wedging process. The modification of valves, such as the aortic valve or atria-ventricular
valves, occurs; and the separation of left and right atria and ventricles is completed to
5

form a regular 4-chamber heart.

15, 19, 20, 19

Any abnormality during these processes can

lead to heart congenital heart defects.

A complete 4-chamber heart, through one organ, functions as two pumps coupled to one
another in a series. The right pump receives deoxygenated blood from the entire body
and pumps it to the lungs for oxygen-carbon dioxide exchange, while the left pump
receives the oxygenated blood from the lung and then delivers this oxygenated blood to
the entire body. As a result, the pressure in the right pump is lower than in the left pump.
However, to perform pumping function, both the left and right pumps need to match their
output volume.

1.3.2. Gross anatomy of the heart
Each side of a heart has a main pumping chamber (the ventricle), a holding chamber (the
atria), and two valves to prevent back flow (Fig. 1.2.). The valve between the right atria
and right ventricle is the tricuspid valve and between the left atria and left ventricle is the
mitral valve.21, 22 These valves prevent the retrograde flow of blood back into the atrium
when the ventricles contract. The pulmonic valve and aortic valve in the right and left
ventricle respectively prevent the blood in the pulmonary artery and aorta from flowing
back to the right and left ventricle when these ventricles relax. The two ventricles share a
common wall (septum) and electrical system to stimulate and control the timing of native
ventricular contraction.

6

Figure 1.2: Schematic image of the heart gross anatomy.
(http://healthinformation.4arabs.com/heart/2.html)

Deoxygenated blood from the vena cava system flows to the heart and is held in the right
atria. When the tricuspid valve opens, the blood flows into the right ventricle in order to
be pumped to the lung where the exchange of carbonate-oxygen in the blood occurs.
Through the pulmonary artery, the oxygenated blood is then brought to the left atria and
finally is pumped into the left ventricle when the mitral valve opens. The contraction of
the left ventricle pumps the blood into the aorta from where blood is delivered throughout
the body. Due to the vascular resistances and pressures being higher in the systemic
circulation than the pulmonary circulation, the left ventricle generates more force to
pump. Therefore, the muscle wall of the left ventricle is thicker than the right ventricle.
Atria act as a booster pump and hence the walls of the atria are also much thinner than the
ventricles.21, 22

7

1.3.3. Working of the heart
The heart, consists of two atria and two ventricles, is the organ responsible for pumping
blood throughout the body. The electrical signals generated in the sino atrial node travel
through a signal transduction pathway to stimulate the heart tissue. In response to this,
the upper then lower chambers of the heart contract sequentially, first both atria, then the
ventricles. The working principle of the right heart side is similar to the left heart.

A pumping cycle of the heart can also be divided into two main periods: the diastolic and
systolic periods. The diastolic period starts when the aortic valve closes and the muscles
begin to relax. The diastolic period ends when the mitral valve closes after filling the
blood from the atrium to the ventricle. The systolic period then starts when the mitral
valve closes and the muscle begins to contract. This period ends when the aortic valve
closes after the blood in the ventricle is ejected to the aorta.21-23

The relationship between pressure and volume, especially for the left ventricle (LV)
chamber, can be divided into four phases: the ventricular filling or diastole, isovolumic
contraction, ejection, and isovolumic relaxation (Fig.1.3.).21-24 During the ventricular
filling phase, the relaxation of the heart muscles reaches the maximum level. Therefore,
when the blood from the atria continues to fill in the ventricle, the pressure of the
ventricle goes up gradually and the blood volume is increased significantly, which is
represented by phase ‘a’ on the pressure-volume loop. When the ventricle pressure
reaches a certain level, the muscles contract.24 The pressure inside the ventricle at this
point is higher than the atria. As a result, the mitral valve closes, but this pressure is not
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sufficient to open the aortic valve.

Because all valves are closed, the pressure is

increased dramatically while the volume remains the same. This phase is called the
isovolumic contraction phase (phase b). At this point, the ventricle begins to contract
until the pressure inside the ventricle chamber exceeds the aortic pressure; then the aortic
valve opens. The blood inside the left ventricle is then ejected to the aorta, causing a
decrease in volume (phase c). However, since the ventricle is still contracting, the
pressure inside the ventricle keeps increasing until it reaches its peak, then, decreases
when the ventricle begins to relax. The ventricular pressure begins to drop until the
pressure in the aorta finally becomes larger than in the ventricle, causing the closure of
the aorta valve. The relaxation of the ventricle plus the closure of valves greatly reduces
the pressure inside the ventricle while the volume remains unchanged with no blood
going in or out of the ventricle. This phase (phase d) generates a vertical line (isovolumic
relaxation phase) on the diagram B (Fig.1.3.). When the pressure inside the LV is lower
than the left atria pressure, the mitral valve opens and the LV is again filled with blood.
The next cardiac cycle begins.21-24

During normal adult conditions, the human heart rate is about 70 ± 10 beats per minute
(bpm). The stroke volume is about 60 ± 10 mL/beat and the left ventricular systolic peak
pressure approximates of 120 ± 10 mmHg. The left ventricular end diastolic pressure
ranges from 5-12 mmHg.

25, 26

. Stroke volume is the volume of blood ejected for each

beat. Heart rates vary during fetal development and are then higher in the neonatal and
adult heart.

9

Figure 1.3: Relationship between pressure and volume during the pump cycle of the
heart. (A) Cardiac cycle diagram and (B) Pressure-Volume Loop. (a) Diastolic filling
phase, (b) Isovolumic phase, (c) ejecting phase, and (d) Isovolumic relaxation phase.

1.4.

HEART AT CELLULAR LEVEL

1.4.1. Cellular organization of cardiac tissue
Unlike other tissue, in the early development, embryonic cardiac tissue has a high ability
for both differentiation and proliferation.27-29 This high proliferation and differentiation
makes the vertebrate heart quickly transformed from a single two-layer straight tube into
a four-chamber heart.30 Cardiac morphogenesis occurs during the embryonic period,
between weeks 4 to 8 in human pregnancy, or between days 2-10 in the chick embryo.16
DNA synthesis reaches the high rate during this cardiac morphogenesis; and the cardiac
conduction system as well as coronary vascular system develops in late morphogenesis.16,
31

However, when entering the neonatal period, cardiomyoctes reduce their proliferating

rate to focus more on producing contractile proteins; hence, becoming functional
cardiacmoyctes.32

Therefore, cardiomyocyte differentiation occurs to adapt the
10

subsequent of hemodynamic pressure/volume loading and unloading, resulting in an
increase in size or causing cell hypertrophy.

During this hypertrophic process, the

amount of protein contents (especially contractile proteins) per individual cell increases
with a little change in cell number.33, 34 After birth, cardiomyocytes lose their ability to
proliferate.

The embryonic cardium is composed of three different major cell layers: an inner single
cell endocardial layer, a loose connective tissue layer and the layer of cardiomyocyte
muscle cells (or myocardium layer).14,

21, 22, 35

During the morphogenesis,

via

proliferation and differentiation of cardiomyocytes, these three layers are quickly
transformed into a 3D trabecular myocardium. (Fig. 1.4.A) This trabecular and compact
myocardium continues to increase in mass and number in order to form a solid mature
myocardium to sustain the transmural pressure due to the hemodynamic loading and
unloading applied on the inner side of the cardiac muscle wall.16 Hence, the developing
of this solid mature myocardium promotes the myocardium function. 36, 37 To perform
this function, under the effect of mechanical load, mature cardiomyocyte and myofibril
arrange in parallel. 35

Cardiomyocytes are the cells that make up the heart muscle and have the ability to
contract spontaneously. To perform their function in synchrony, cardiomyocytes need to
align and establish end to end cell-cell contacts. (Fig.1.4B and C). Smooth muscle cells
form a contiguous layer over the cardiomyocytes, and finally a layer of endothelial cells
line the myocardium providing shear protection. Besides these major cell types, cardiac
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tissues are also composed of cardiac fibroblasts. Cardiac fibroblasts relate to heart
remodeling, therefore, play a critical role in heart hypertrophy and heart failure.38
[A]

[B]

[C]

Figure 1.4: Cardiac tissue. [A] Schematic layers of the heart walls; [B] Histological
image of ventricular wall; [C] Arrangement of cardiomyocytes in the cardiac muscle.
([A] 39; [B] http://www.studyblue.com/notes/note/n/histology-medi-1000/deck/938131;
[C]:http://www.studyblue.com/notes/note/n/tissue-lab-3-muscle-and-nervoustissue/deck/2179334)
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Hemodynamic stimulation is one of the major exogenous factors regulating cardiac
morphogenesis. To adapt mechanical loading and unloading, the myocardium increases
the cell size with protein contents, especially the contractile regulating proteins. 16,

40

Myofibril is the contractile structure of cardiac muscle. Myofibrils are composed of
sarcomeres or the contractile unit.

41, 42

At the beginning, when the cardiac muscle cells

differentiate, all the sarcomeric proteins randomly diffuse in the cytoplasm. By the time
of linear-heart-tube formation, due to mechanical stimulations, myocytes begin to beat or
contract, causing myofibrils to rapidly arrange into a highly organized network in order to
synchronize the contractions throughout. A sarcomere unit is composed of 3 major
components: thin filament, thick filament, and Z band. (Fig. 1.5) Thick filaments arrange
in parallel to the thin filaments. Myosin heavy chain proteins are on the thick filament
and bind to F-actin of the thin filament during the contraction. Thin filament is composed
of F-actin, troponins, and tropomyosin. During the contraction, thick and thin filament
slide along each other. Titin filament connects the thick filaments to the Z band and acts
as an elastic spring during the myocyte contraction. The Z band connects the sarcomere
units in series.42-44 The contraction is controlled by the interaction between the myosin
heavy chain on the thick filament and the binding site of the F-actin molecules, which is
the major component of the thin filament.

This binding activity depends on the

sensitivities of Ca2+ to the tropomyosin-troponin complex.45 Alpha-actinin, a component
of Z band, serve as the anchor for F-actin to Z band, as well as the connection to neighbor
sarcomere.46 The mechanism of the contraction will be discussed in the section 1.4.2.
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[A]

[B]

[C]

Figure 1.5: Simplified schematic model of mature myofibril. [A] Myofibril; [B]
Ultrastructure of a relaxing sarcomere; [C] Ultrastructure of a contracting sarcomere.
The magnitude and duration of stretch and contraction in a cardiac tissue depends on the
preload and afterload conditions. In the heart, specifically in the left ventricle, preload
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refers to the condition when the filling of the blood inside the ventricle causes the stretch
of the ventricular wall during the diastolic phase. Afterload refers to the aortic resistance
that the system needs to overcome in order to pump blood out of the ventricle via opening
of the aortic valve.22 This directly affects the contractile force that needs to be generated
by cardiomyocytes. Overcoming the aortic pressure opens the aortic valve for ejecting the
blood into the aorta.

Preload pressure increases slowly when blood filling to the chamber during diastole
increases, which creates greater systolic pressure for the subsequent contractions due to
the preload sensitivity of the native ventricle. This systolic pressure continues to increase
until its maximum systolic pressure is reached at the optimal preload. At a constant
preload, higher systolic pressure can be obtained through ventricular contraction by
raising the afterload condition such as increasing the aortic pressure.22 However, if the
afterload pressure or the resistance keeps increasing, the ventricle cannot create enough
force to open the aortic valve to push the blood out of the heart. At this point, the systolic
phase is totally isovolumic. Preload and afterload pressures, as a result, depend on the
vascular system and the behavior of the heart including peripheral resistance, the
frequency of the heart’s contraction, and change of the stroke volume.22

1.4.2. Cellular response to mechanical signals
When a mechanical stimulus is applied to the extracellular matrix (ECM), the cells detect
this mechanical stimulus via mechanoreceptors. These mechanoreceptors are located in
the plasma membrane connecting the extracellular and intracellular regions of the cells,
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traducing the mechanical signals from the outside to the inside of the cell. 23, 47

Once the

signal is transmitted inside of the cell, the signal triggers biochemical changes via
signaling transduction pathway, enhances the formation of sarcomere, and alters structure
of the cytoskeleton directly.23, 47

Troponin complex includes troponin C (TnC), troponin I (TnI), and troponin T (TnT).
TnC is Ca2+ sensitive and has a site for Ca2+ binding; TnI is the contractile inhibitor; and
TnT is the protein binding to tropomyosin. This troponin complex is strongly associated
with the tropomyosin, which regulate the binding of MHC to the thin filament for
sarcomeric contraction.

48-50

Binding Ca2+ to TnC switches the conformation of TnC

from a close position to the open one, allowing the interaction of TnC with TnI to
happen. Without this interaction, TnI binds to F-actin at the binding site of MHC; thus, it
prevents the bonding between MHC with F-actin. Binding of TnC-TnI releases the
binding of TnI-actin and enhances the binding of TnI-TnT, which reveals the binding
sites of MHC for MHC attachment.

Once MHC attaches to the F-actin, with the ATP

hydrolysis occurring during the association of Ca2+ with TnC; contraction takes place. 41,
50, 51

The relaxation of the sarcomere unit occurs during the dissociation of Ca 2+-TnC.

Ca2+ is then transferred back to SR via the SERCA2a pump. In summary, calcium ion
will bind to the troponin C, help to deactivate troponin I (inhibitor) and change the
formation of TnT in order to reveal the MHC binding site on the thin filament. Once the
binding site is opened, myosin heavy chain from the thick filament binds to F-actin. This
binding pulls the thin filament of a sarcomere closer to the center, causing the
contraction. Titin is a protein connecting the thick filament to the Z band at this point
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serves as an elastic spring, keeping the thick filament at the center during this contraction.
Alpha actinin, a protein located on the Z bands, helps to connect the thin filament with
the sarcomere, as well as to the thin filament of the neighbor sarcomere. Alpha actinin
thus contributes to form and maintain the lattice networks among the sarcomere during
the relaxing as well as the contracting phases.

Catecholamine affects mechanical performance of the heart tissues through the activation
of β-adrenergic receptors (AR) and cardiovascular function can be positively and
negatively controlled primarily via adrenergic signaling.52-54 Under normal physiological
conditions, catecholamine induces positive inotropic and lusitropic responses in the heart
tissue through β1-AR-activated pathway. Once the stimulation of β1-ARs binding with
its agonist (ex. isoproterenol) happened, this binding complex activates the formation of
cyclic AMP (cAMP). cAMP accumulation rapidly increases which indirectly promotes
the phosphorylation of PLB, and enhances the cardiac contractility.

47

Even though the

density of β-ARs in utero diminishes during development,55 there are shifts in the
adrenergic receptor subtypes with increasing dominance by subtype β1-ARs as
cardiomyocytes become more mature under normal physiological condition.53,

56

This

dominant β1-ARs, therefore, induces positive inotrope and lusitrope via heart rate and
contractility. Under the abnormal physiological condition of the heart, or failing heart,
β1-ARs decreases, and β2-ARs increases with increasing sensitivity to adrenergic toxicity
resulting cardiomyocyte death.56
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Increasing

cAMP

promotes

the

phosphorylation

of

phospholamban

(PLB).57

Sarcoplasmic reticulum calcium ATPase2a (SERCA 2a) and PLB are proteins for
calcium handling regulation inside the cardiomyocytes (Fig.1.6). These proteins are
involved in regulating the contraction-relaxation of the heart muscle. Phosphorylated
PLB enhances the activity of SERCA2a by increasing the affinity of Ca 2+ on SERCA2a.
This activated SERCA2a then transports calcium against the gradient from cytoplasm
back to sarcoplasmic reticulum (SR) for muscle relaxation.58

Phosphorylated PLB

(pPLB) releases this inhibitory effect, making the affinity site to Ca2+ on SERCA2a more
apparent. As a result, the rate of calcium ions influx back to the SR increases, promoting
the muscle relaxation and being ready for the next contraction.

Without being

phosphorylated, PLB binds to SERCA2a, preventing the Ca2+ binding to SERCA2a, and
hence becoming an endogenous inhibitor of SERCA2a.

Figure 1.6: Simplified schematic of the biomechanical pathway relating to calcium
regulation inside the cell for cardiac contractility.
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Sarcomere length, a basic contractile unit of cardiomyocyte, can be affected by the
mechanical stimulation.59 When the muscle is stretched to a length greater than normal
size, new sarcomere units are added rapidly at the end of the muscle fibers. 60, 61 Unlike
the skeletal muscle, small changes in sarcomere length can result large changes in tension
generation.59,

62, 63

Therefore, increasing the sarcomere length enhances the tension

development, which affects the changes both in preload condition and the contractility of
the heart.

TnT and Alpha and Beta-Myosin Heavy Chain (α, β-MHC) are proteins involved in
cardiac sarcomere function as discussed previously.

TnT is one of three troponins

binding with tropomyosin. TnT affects the function of thin filaments and the interaction
between the thin and thick filaments, regulating cardiac muscle contractility. 50
Abnormality of this TnT gene can cause sudden death for cardiac patients. 45

Myosin heavy chain (MHC) is a major protein expressed in heart tissue during the
developmental stage and is responsible for mechanical performance of the heart,
especially muscle contractility.64-66 In higher vertebrates, two cardiac isoforms of MHC
predominate. β-MHC is expressed mainly during embryogenesis or heart diseases while
α-MHC exists dominantly in the adult heart tissue and inhibits the expression of β-MHC.
The temporal expression of α and β-MHC is species specific.
distribution of α-MHC expression is correlated with beating rate.67
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Interestingly,

the

In addition, the deformation of the cytoskeleton can change the physical properties of the
cells and distort the nucleus, as well as the biochemical and molecular events inside the
cell, such as gene expression, transcription, translation and protein synthesis.

This

change also affects physical and chemical communication between cells. Therefore, the
structure inside the cell, morphology of cell, and the biochemical aspects of the cell are
altered as a result of mechanical stimulus.

To respond to any abnormal condition of mechanical stimulations, such as overpressure
or overstretch, the heart begins to remodel itself. The remodeling of the hearts causes an
increase in the number of fibroblasts, thickens the heart muscle wall, or enlarges the size
of the hearts.61, 68, 69 These changes play critical roles in contractility of the cardiac tissue.
If the abnormal mechanical stimulus persists, heart remodelling can lead to the cardiac
dysfunction (Fig. 1.7)

Figure 1.7: Maladaptive responses due to abnormal mechanical loading leads to the
heart failure.
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1.5. CONCLUSION
The heart is the central organ within the cardiovascular system and is extremely complex
in terms of construction and function. This chapter serves to provide an overview of
CVD and the heart structure and function.

CVD is a serious health problem and

continues to claim millions of lives each year while also diminishing quality of life for
several others.

However, current treatment options, though beneficial have several

limitations. In order to improve the quality of life, researchers therefore continue to
search for better options to prevent or treat the CVD.
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CHAPTER 2
IN-VITRO MODEL SYSTEMS TO STUDY CARDIAC TISSUE
2.1. NEED FOR CELLULAR-LEVEL STUDIES
The human body consists of sequential levels of structural and functional organization.
Cells are the smallest functional units capable of sustaining themselves and consist of
various molecular constituents, including bio-molecules like DNA, RNA and proteins.
Cells are organized together to form tissue.

Organs in the body responsible for

specialized functions are made up of one or more types of tissues. Various organs and/or
tissues in the body are organized together to form systems (Ex: Cardiovascular, Nervous,
or Circulatory). Finally, an organism sustains life due to synergistic working of various
systems within the body. Several mechanisms exist to provide feedback and maintain the
body’s functions within a tight range (homeostasis).

The tradeoff between generations of highly specific molecular information and
translation of that information in-vivo necessitates investigation at various levels of
cellular organizations (Fig.2.1).

Cell-based studies are essential to provide highly

specific information relating to molecular mediator and the targets for drug discovery,
therapy, and tissue generation. Analysis of purified or isolated cell populations free from
surrounding cellular and extracellular constituents allows the investigation of sub-cellular
mechanisms in great detail, which is not possible in intact tissues.70 Study of
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heterogeneous mixtures of cells (like in a tissue) often results in unnecessary noise, which
significantly deteriorates the quality of information attainable.

Figure 2.1: Biologic complexity versus clinical translation plot. Human clinical studies
are the most relevant, by definition, to clinical translation, but have the least specific
whereas cellular level studies provide highly specific information but their relevance to
human physiology is low. The in vitro cell cellular model devices seek to significantly
enhance the relevance of cellular level studies.

Further, cellular level systems that utilize purified cells, allow for convenient analysis,
using both destructive and non-destructive techniques.

Cells can be imaged using

microscopy to study structure, conformation, the expression of intra and extra-cellular
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markers, organization of organelles and other details of nuclear and cytoskeletal
elements. Low and high-throughput techniques can be used to evaluate gene expression,
protein expression and production of metabolites. The effect of a drug can be understood
in terms of molecular signaling events that alter cell phenotype and function. Highthroughput cell culture, using multi-well plates, can be used to evaluate effects of
variables, including concentration of stimulants and time of exposure on cellular
function.71 The flexibility and specificity of information generated from cellular level
systems is unparalleled, and is usually an essential first step in any drug discovery study
or tissue generation. However, since cell-based studies use isolated cells in a nonphysiological environment without mechanisms responsible for homeostasis, the
relevance of these studies is limited, and results need to be verified using animal and
patient level studies.

In-vitro studies are performed in isolation without the biologic complexity and the
paracrine feedback mechanisms present in the body. Therefore, to understand the real and
long term effects of a biochemical compound, foreign tissue, drug, or device on an organ
or in a system, in-vivo evaluation is essential. Animal studies are used to confirm
outcomes before application in the human body. Animals are similar in complexity to
humans; and the levels of organization are conserved amongst most species. Small
animal studies, like study on rats, mice, hamsters and rabbits, are easier to perform due to
cost related issues and availability of significant amounts of information and
characterization of various systems in animals.61, 72 Further, technologies for generation
of transgenic animals allows for greater flexibility with design of studies to evaluate
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targeted pathways.73 Large animals are physiologically closer to humans and provide
improved relevance due to greater similarities in size of organs and function of
systems.74, 75 Large animals are particularly useful in testing organ/ tissue transplantation
or implantable medical devices because the size of their organs is comparable to humans
and provides a more accurate representation of the actual situation.

Patient or clinical studies are often the last stage of evaluation for a particular drug or
treatment. This follows pre-clinical studies accomplished using in-vitro methods and invivo animal studies. Clinical trials allow assessing the safety and effectiveness of a new
medicine or device on patients. Clinical studies are divided into phases 0, 1, 2, 3, and 4.
Phase 0 trial allows an early evaluation of the pharmacokinetic effects of the candidate
drug in humans. This is done by administrating a low dose of the test compound in a
short time period. This phase 0 trial doesn’t have a therapeutic or treatment purpose;
rather, allows the researchers to explore the pharmacological profile of the test compound
in human to see if it is appropriate for humans or not.76 As a result, it helps to select the
potential drug. The disadvantage of this phase is the poor relation between the preclinical
and clinical effect of the testing drug.77 Phase 1 is the first stage to test the dose effects
on human subjects, so the appropriate dose of a certain drug on humans can be found.
Phase 2 trials assess how well the drug works and continues to affirm the safety of the
drug on large groups. Phase 3 trials are applied on a huge group to see how effective the
drug is for a certain type of disease. And finally, phase 4 post-marketing surveillance
trials determine potential unanticipated effects of the drug in broader, unselected
populations.
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In conclusion, cell-level studies are highly specific and can be used to investigate
molecular mediators and signaling pathways involved in disease processes. These studies
cannot be accomplished in patients because of inherent difficulties with isolation of cells
and analytical techniques.

Animals provide a more appropriate platform for early

evaluation as they provide more opportunities for evaluation.

To shorten the time

between discovery and clinical validation, it is essential that cell-based studies are
accomplished in platforms that have physiological relevance. For example: studying
cardiac tissue under unloaded static conditions is undesirable since mechanical loading
and fluid flow play an important role in maintaining cell structure and phenotype.

2.2. IMPORTANT CONSIDERATIONS FOR CELL-LEVEL METHODS OF
CARDIAC TISSUE DEVELOPLMENT AND CHARACTERIZTION
During normal heart function, the myocardium experiences passive stretching and
increasing transmural pressure during filling (preload) and actively generates mechanical
force with further increase in wall stress during ejection (contraction). Cells in cardiac
tissue therefore are under constant physical stimulation and rely on the conversion of
these cues into intracellular signals to control cell phenotype and muscle mass during
physiologic and pathologic conditions.78 Cardiac cells therefore are exposed to periodic
stress, strain, and shear.

Physiological heart development and cardiac function rely on the response of cardiac
tissue to mechanical stress signals during hemodynamic loading and unloading. These
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stresses manifest themselves via changes in cell structure, contractile function and gene
expression.72 Disruption of this well-balanced stress-sensing machinery due to various
pathological conditions results in mechanical dysregulation, cardiac tissue remodeling
and heart failure. To achieve physiological relevance, in-vitro models must replicate the
complex, dynamic in-vivo interactions between cardiomyocytes and mechanical stress
signals. However, current in-vitro models do not incorporate all aspects of mechanical
loading and therefore fail to accurately mimic the in-vivo cardiac microenvironment.

2.3. REVIEW AND CURRENT STATE OF THE ART
Several animal model studies have proved that hemodynamic mechanical stimulations
play significant roles in shaping the formation and ensuring proper heart functions. 19, 79-84
Therefore, for cardiomyocyte differentiation into functional cardiac tissue, in-vitro
mechanical stimulation should be included during in-vitro cardiac tissue regeneration.

Various clinical studies for cardiac tissue regeneration via transplantation of progenitor or
differentiated cell population have been established.85-87 However, the goal of tissue
replacement with functional myocardium has not accomplished because a majority of
studies apply the direct delivery of undifferentiated cardiac cells to the injured
locations.88

In addition, the current state of cardiovascular in-vitro models is

predominantly cultured under conventional static conditions.69, 70, 89 Most studies utilize
isolated cardiomyocyte cells maintained in two-dimensional culture forming randomly
oriented cell-extracellular matrix (ECM) interactions.73, 90, 91 Culturing cardiomyocytes in
a 2D system does not reflect the physically biological environment that the in-vivo
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cardiomyocytes experience. As a result, the phenotype and behavior of these 2D cultured
cardiomyocytes appear differently from the cardiomyocytes in the in-vivo normal
conditions.92 Cardiomyocyte grown on the 2D condition shows flattened, stellate-shape
phenotype instead of a rod-shape phenotype as it is in the in-vivo environment.
Proliferation rate, differentiation, and DNA synthesis are poor.16,

93, 94

The interaction

between cell-cell or cell-matrix are limited due to the 2D planar geometry; thus, cell-cell
connections are loose, which fails to initiate spontaneous contraction.

There are groups using 3D engineered cardiac constructs to investigate cardiomyocyte
maturation, response to drugs, and the effects of genetic defects in ion channels and
sarcomeric proteins. The phenotype and molecular regulation and the function of
cardiomyocytes in 3D shows more likely resemble the in-vivo cardiomycytes.

16, 92-100

However, there are a limited number of bioreactors that can generate 3D tissue on a scale
relevant for clinical translation. Complex systems that can replicate in-vitro mechanical
stimulation occurring in the heart are currently unavailable. Accurate replication of the
in-vivo environment requires consideration of several factors. First, tissue orientation and
direction of stretch are critical determinants of cardiac cell signaling; therefore randomly
oriented cultures cannot replicate physiological loading.

Second, fluid flow is an

important factor as shear stress strongly influences endothelial and smooth muscle
phenotype but not cardiomyocytes. Third, cyclic build-up of pressure and stretch during
preloading are critical determinants that dictate cell structure and function; hence,
perfused systems are more representative of the in-vivo environment.
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Fourth,

synchronous contractions ensure ejection of fluid that in turn results in relaxation of builtup pressure and stretch.38

Some of the aforementioned issues have been previously addressed, albeit individually.
Patterning techniques like micro-contact printing and lithography to define areas of cell
attachment and directional alignment have been accomplished.101-103 Several groups have
cultured cardiac cells under continuous and cyclic loading conditions to mimic in-vivo
hemodynamic loading.104-107 Commercial technologies like Flexercell® Strain -FX-4000
Flexercell Tension Plus(TM) (http://www. flexcellint.com), which consists of a flexible
membrane on which cardiac cells can be plated and then be subject to oscillatory
deflections using a vacuum or pressure source, have been used to apply mechanical
stretch.96, 108 Electrophysiological studies utilize systems such as the IonOptix Myocyte
Systems (http://www.ionoptix.com) where cardiomyocytes grown on a glass slide are
stimulated with an electrical impulse and analyzed for contractility. However, to the best
of our knowledge, no in-vitro system currently replicates all aspects of cardiac
mechanical loading and unloading in the heart.

2.4. PHYSIOLOGICALLY RELEVANT SYSTEMS FOR CARDIAC CELL
CULTURE
Various manifestations of cardiovascular diseases directly correspond to changes in
mechanical behavior of cardiac cells.

This, in turn, affects cellular phenotype and

function, causing changes like hypertrophy, growth of fibrous tissue, and establishment
of random cellular orientation.69 For example, in hypertension, the pressure inside the

29

heart exceeds the normal range due to a high resistance in vascular system and eventually
results in hemodynamic overloading of the heart and vasculature.

This higher

intracardiac and transmural pressure triggers myocytes hypertrophy initially and
subsequently can lead to a dilated phenotype associated with myocytes loss. In the long
term, this additional stretch weakens the heart muscle, causing heart failure. 61 In the
contrast, hypotension refers to the condition where the pressure inside the heart is lower
than the normal range due to abnormal filling or ejection or where the arterial vasculature
is abnormally dilated. This causes reduced blood circulation and oxygen deprivation to
the rest of the body.

In response to this oxygen deprivation and reduced nutrient

delivery, the heart rate increases, resulting in altered stretch and pressure profiles.

The frequency of the loading determines the ranges for normal and abnormal heart
function.

For example, in human, bradycardia is a condition where the heart rate is

lower than 60 bpm, and tachycardia is another condition characterized by a significantly
higher heart rate (>200 bpm) in comparison to normal heart rate (~75 bpm). In response
to these abnormal patterns, the heart either lowers or increases the systolic fraction. 109 All
of these changes can cause the reorganization of cardiac tissue and it can lead to heart
failure or sudden death if it persists long term.110

Finally, due to fluid flow, shear stress can be a significant mechanical cue for cardiac
endothelial and cardiac smooth muscle cells. Cardiac endothelial cells contribute to the
internal lining of the myocardium and are directly exposed to fluid induced shear stress
during hemodynamic loading and unloading.
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Changes in magnitude, frequency, or

duration of shear stress are crucial for the structure, function and permeability of
endothelial cells. Various clinical conditions occur as a result of changes to shear
profiles seen by cardiac endothelial cells.

Studying cardiovascular disease requires appropriate cellular level platforms which can
be used to culture cells while accurately mimicking mechanical and fluidic loading
conditions seen in-vivo. In cardiovascular disease, various conditions are associated with
distinct mechanical loading profiles and replication of those profiles is critical to ensure
proper understanding at the cellular and molecular levels. Mechanical loads experienced
by cardiac cells vary as a consequence of dysfunction including pressure, stretch and
shear stress, as well as the frequency and duration.

2.5. IN-VITRO TECHNIQUES FOR MECHANICAL STIMULATION OF CELLS
Cells in different tissues experience cyclic compressive loads. Cardiac and vascular
tissues are examples of tissue where cells within the tissue are constantly under
compressive loading. Replicating this condition in-vitro can be accomplished using
different techniques such as application gas pressure (hydrostatic compression) directly to
the culture system or through the fluid induced loading of the system (pressure loading).
These techniques cause direct application of pressure to cells in culture mimicking
conditions seen in-vivo.

Another commonly seen loading condition in cardiac and vascular tissue is cyclic stretch
(and strain). The most common approach to stretch the cells in culture is by growing the
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cell on a flexible surface and applying stretch on the surface where the cells are attached.
The stretch can be uniaxial, biaxial, and include shear. With the uniaxial stretch, the
surface is either rectangular or square and is stretched in one direction either
longitudinally to both ends, or is bent/flexed in a four-point bending. With the biaxial
stretch, the membrane is circular and the edge of the membrane is fixed. The applied
pressure deforms the membrane in both the radial and circumferential directions.
However, the strain depends heavily on the location on the membrane, causing the cells
on different locations to stretch differently. For example, cells seeded at the center will
stretch more than those at the edges. As a result, it is extremely complicated to analyze
the data and to interpret the cells behavior. To produce the equi-biaxial strain, the
membrane has to slide non-frictionally on a stable plane. On this plane, the stress
distribution on the area of the membrane where it is supported by the plane, is
symmetrical, creating an isotropic and spatially constant strain.

Finally, cells in different tissues experience shear stress as a consequence of fluid flow.
Shear stress is a key mediator of cells phenotype. Shear stress controls alignment and
establishes cell-cell contacts, which are important in the formation of tight junctions in
ensuring low permeability in vasculature. The velocity, as well as the pattern of the flow,
laminar versus turbulent flow for example, can create different shear stress on the cells.
Also, viscosity of the fluid is another factor that can increase or decrease shear stress on
the cells.
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In cardiac and vascular tissue, all three of these loads (cyclic pressure, stretch, and shear
stress) are experienced simultaneously. Additionally, changes in one or more of these
loads have a cascading effect on the entire system. Therefore in-vitro models of cardiac
tissue need to mimic accurately the combined effects of cyclic pressure, stretch and shear
in a pulsatile fashion.

2.6. CONCLUSION
Based on the discussion above, due to the complex nature of the heart and the importance
of mechanical loads, an in-vitro cellular culture model designed with physiological
relevance is critical to investigate the cellular and molecular adaption of cardiac cells and
tissues relevant to cardiovascular adaption and disease.

No device or cell culture

platform is commercially available today to accomplish long term culture of cardiac cells
in-vitro with accurate replication of realistic mechanical loading profiles. Efforts by
other groups thus far have succeeded in replicating isolated mechanical loads. There is
still a need for platforms where the culture conditions can be dynamically varied not only
to replicate normal loading conditions, but also abnormal loading conditions. These
platforms are necessary to study the molecular pathophysiology of cardiovascular
diseases and in the discovery of drugs, treatment options and cardiac cell regeneration
strategies.
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CHAPTER 3
THE µCCCM SYSTEM
3.1. INTRODUCTION
Understanding the molecular basis of manifestations of cardiovascular disease requires
multiscale and multilevel approaches and an appreciation of the developmental
mechanisms that regulate cardiac morphogenesis and remodeling.

Because

cardiomyocyte cell death is the major cause of cardiac pathology leading to heart failure,
many eﬀorts are underway to restore cardiac tissue structure and function through
regenerative approaches.69 Unfortunately, unlike most cells in the body, cardiomyocytes
stop diﬀerentiation and have limited proliferative potential after birth in higher
vertebrates.101 To accommodate, scar tissue replaces the damaged cardiac tissue. Scar
tissue increases the stiffness of the heart tissue and cause the inability to regenerate the
same contractile forces as the normal undamaged cardiac tissue does. Therefore, cardiac
tissue engineering plays a significant role in the process to find better treatment of heart
disease due to the loss of cardiomyocytes.

However, replicating all aspects of the

mechanical loading and unloading environment for the in-vitro cardiac cultured cells is a
challenging task as discussed in chapter 2. It is because the myocardium experiences
passive stretching and pressure build-up during ﬁlling (preload) and actively generates
mechanical force during ejection (contraction) against variable afterload. Cells in cardiac
tissue are under constant physical stimulation and rely on conversion of these cues into
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intracellular signals to control cell phenotype and muscle mass during mechanical
conditions. Therefore, to study the molecular pathophysiology of cardiovascular diseases,
in the discovery of drugs, treatment options, and cardiac cell regeneration strategies, invitro cardiac tissue must be cultured in the in-vivo like environment.
The need for platforms where the culture conditions can mimic the physiologically
mechanical condition and can be dynamically varied to normal and abnormal
environments necessitates engineers to design different cell culture models. With a
primary goal of replicating such in vivo mechanical loading conditions for in-vitro
cardiomyocytes and to enable cardiac tissue generation, a microfluidic cardiac cell
culture model (µCCCM) was developed.111 The first generation of the cardiac cell
culture model was built in 2008 in order to mimic cyclic mechanical strains and pressures
experienced by cells during the cardiac cycle. With this model, cardiac cells undergo
cyclic stretch and contraction, pulsatile pressure, as well as fluid loaded and ejected.

3.2. THE µCCCM
The µCCCM system consists of a peristaltic pump, cell culture chamber, pulsatile
actuated collapsible valve, and a tunable resistance in a series, along with accessories
including tubing, an oil chamber, a pressure generator, and a digital manometer. (Fig.
3.1)
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Figure 3.1: Assembled µCCCM for cell culture experiment. The tunable valve and
collapsible valve were placed downstream of the cell culture platform to create the
resistance and pulsatile pressure inside the cell chamber. Cell culture chamber (pink
color) was clamped between two fixtures of the cell culture platform. The µCCCM
system has a closed circulating fluid network.

Cells were placed in culture on a thin PDMS membrane attached at the bottom of the cell
culture chamber inside the platform. Continuous circulation of culture medium is
maintained using a peristaltic pump. Downstream the chamber is a collapsible valve
actuated in a pulsatile fashion using a pressure generator. Closure of this collapsible
valve leads to pressure build up in the chamber, which in turn also leads to stretching of
the thin membrane as well as the cells on this membrane. This stretching phase mimics
the diastolic loading phase in the ventricle. To ensure uniformity, a post is placed
beneath the thin membrane such that, during stretch, the portion of the membrane on
which cells are cultured experiences uniform strain and the edges experience larger nonuniform strain (Fig. 3.2). Lubricating oil fills in the chamber beneath the cell culture area
to create friction-free sliding of the membrane on the post. Further, to influence outflow
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resistance, a tunable homeostasis valve is placed downstream of the collapsible valve to
mimic afterload. Fluid transport and subsequent shear stress can be controlled by varying
the pump flow rate. Pressure buildup and strain can be controlled via a combination of
factors, including the thickness of the membrane, fluid flow rate, and operation of both
valves

Figure 3.2: Setup design for equi-baxial strain. A significant deformation at the edges of
the membrane occurs when the pressure is applied, but the area of the membrane rested
on the post has the same radial and circumferential strain.
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3. 3. FABRICATION AND ASSEMBLY OF THE µCCCM
3.3.1. Assembly for Housing the Cell Culture Platform and the µCCCM
components
The assembly for housing the cell culture platform was fabricated in the Rapid
Prototyping Facility at the University of Louisville using Computer Numerical Control
(CNC) Milling Machine. The designs were laid out using Solidworks 3D layout software
prior to machining the assembly using CNC milling. Acrylic was used for construction.
(Fig. 3.3)
[A]

[B]

Figure 3.3: Schematic representation of the top and bottom fixtures of the platform for
housing the cell culture chamber. [A] The top fixture has the fluid inlet and outlet
accesses; [B] The bottom part of the platform has two rectangular holes at the center.
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The cell culture chamber (~1cm diameter) and oil chamber were made from polydimethyl
siloxane (PDMS) (Dow Corning, ratio 1:10 of the curing agent and the base) using
standard soft-lithography techniques. The collapsible valve was created mainly via thin
elastic ARGYLE Penrose tubing. More detail information for these fabrications will be
seen in the published article.111

3.3.2. Assembly of the µCCCM
First, an acrylic sheet was placed in the rectangular hole on the bottom piece of the
platform, followed by the oil chamber (Fig.3.4).

Then, the cell culture chamber, with

18G needle inserted, was aligned on top of the oil chamber. The top piece of the platform
was then laid on top of the cell chamber. The platforms were tightened with four screws.
Finally, low viscosity oil was injected into the oil chamber through needles.

A 3-stop Pharmed BPT tube (1.3 mm ID, Cole-Parmer, Vernon Hills, IL) was connected
from a 50 mL medium container to the inlet of the device via a peristaltic pump (Ismatex,
ISM 596D, Vancouver, MA). The collapsible valve was connected from the outlet of the
device to the medium container. The tunable valve was placed downstream of the
collapsible valve (Fig.3.1.). Finally, the pressure sensor was connected to the needle,
which was connected to the cell chamber. A pulsatile pressure generator was connected
to the bottom T of the collapsible valve.
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Figure 3.4: Assembly of the cell culture and oil chambers between the platforms.

3.4. OPERATION OF THE µCCCM
Once assembled as in Fig. 3.1, the peristaltic pump was started gradually from a low flow
rate to the desired flow rate. After 30 min running, the pressure in the pneumatic
pressure generator source was applied and the tunable valve was adjusted until the
pressure reached the desirable values. Variable parameters, such as the frequency of the
membrane stretching as well as the percentage of systolic phase per one cycle, were
determined based on the requirement of each experiment.

The frequency of the

stretching was controlled through the % systolic and the frequency controls on the
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pressure generator source. The pressure inside the cell chamber was varied by the
corroboration between the pressure applied on the collapsible valve and the adjustment of
the tunable valve. The stretching level of the membrane was determined by the thickness
of the membrane, which were measured and standardized appropriately and the pressure
applied on the membrane. And the shear stress on the cells was controlled by the
velocity of the fluid loading and the dimension of the cell culture chamber.

3.5. APPLICATIONS
3.5.1. Pressure profiles
The device was assembled and the pressure build-up within the chamber was generated
for the following clinically relevant experimental conditions – normal, heart failure,
hypertension, hypotension, tachycardia, and bradycardia. To accomplish pressure
monitoring within the chamber, a high-fidelity pressure catheter (Millar Instruments,
Boston, MA) was inserted through a hemostatic valve and syringe needle such that the
pressure sensing element resided in the center of the chamber. The chamber pressure
waveforms were analyzed by using a Hemodynamic Evaluation and Assessment
Research Tool program developed in Matlab (MathWorks, Natick).

The different

waveforms for various physical heart conditions were therefore replicated and recorded
by either increasing or decreasing the pressure in the pressure generator and by adjusting
the tunable valve (Fig. 3.5). These results confirmed that the µCCCM enabled to
regenerate various clinically relevant physiologic conditions of the heart.
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Figure 3.5: Pressure waveforms that simulate various physiologic conditions in the
µCCCM. These conditions include both normal and dysfunctional myocardium, such as
heart failure, hypertension, hypotension, bradycardia, and tachycardia.
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3.5.2. Cell studies for the proof-of concept
H9C2 cells were cultured within the µCCCM system to demonstrate the proof-of-concept.
H9C2 cells were cultured in static condition (control) and within the μCCCM under
pulsatile pressure and stretch, representing normal physiological loading (peak pressures
of 120 mm of Hg, strain of 20% and a frequency of 80 bpm with 50% systolic to
diastolic, flow rate of 8.4ml/min) for 24 h at 37oC and 5% CO2. More detail of cell
culturing is available on the published article. 111

The results showed that cells not only survived physiological loads but also showed the
positive effects of physiological loading. Cells cultured in static condition (control)
attained a fibroblast like morphology (Fig. 3.6a), whereas cells cultured in the μCCCM
were more rectangular, and presented a postage stamp-like morphology (Fig. 3.6b). The
size of the cells cultured within the μCCCM exposed to pressure was larger than those
cultures in static condition.

Staining with Phaloidin showed a low intensity fluorescent color and random orientation
of f-actin in controls in comparison to aligned f-actin in cells cultured with pulsatile
pressure and stretch (Fig.3.6c and d). This indicated that the contraction-stretching of the
cells promotes the increasing % of f-actin and also an increase in the length of the
sarcomere, and helps to align the cells in one direction. The increase in the length of the
sarcomere is the result of the increase in contraction of the cell under pulsatile stretch.
The alignment of the cells demonstrated that mechanical loading spontaneously
rearranged the orientation of the cells.
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P-phospholamban was detected in cells cultured within the μCCCM, however, the
expression of this protein was very low in cells cultured in static condition, as shown is
Figure 3.6e, in comparison to the cells cultured in μCCCM (Fig. 3.6). Phospholamban is
the integral membrane protein. To respond to the contraction of the cells, phospholamban
is phosphorylated. With cAMP, this p-phospholamban promotes the influx of Ca2+ into
the cells to bind to the contractile unit, causing the cells to contract. 112, 113 Therefore,
indirectly, the increasing of activation of p-phospholamban, which was reflected by the
intensive green color on the loading sample, in comparison of the color on the control
sample on the Fig. 3.5.e and f, will be indicative of cell contraction.
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Figure 3.6: Physiological loading promoted the alignment of f-actin and increased
phosphorylated phospholamban activity in H9C2 cells.

Cells were under a static

condition (control) and normal physiological loading for 24 hrs. Notice the directional
alignment of f-actin stress fibers and increased p-phospholamban activity in the loading
condition. (a, b) Phase contrast images; (c, d) Staining with TRITC-conjugated Phaloidin
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for detection of f-actin; (e, f) Immunofluorescence staining for detection of pphospholamban activity; (g, h) Merged images of F-actin and p-phospholamban.

The proof-of-concept demonstrations using the µCCCM system for cardiac culture were
accomplished, confirming that this system has the ability for the design and study of
various conditions with different cell types associated with CVD. These studies can be
cardiomyocyte regeneration using mechanical loading and stem cells, adult
cardiomyocyte regeneration using controlled mechanical loads, study of cardiac and
aortic endothelial cells under conditions of continuous and pulsatile flow

114, 115

and

finally, evaluation of drugs and other treatment options using cardiac cells maintained
under various disease conditions.

3.6. CONCLUSION AND LIMITATIONS
Microfluidics based systems have been used to create cardiomyocyte actuators and
pumps as well as cell models.102,

116-121

The µCCCM was the first system, to our

knowledge, that was developed to replicate the mechanical loading conditions observed
in the heart, which includes the fluid flow, pulsatile stretch, and pressure. The µCCCM
allowed dynamic studies accomplished via the direct manipulation of flow rate, valve
operation, membrane thickness and the height of the cell culture chamber.

We

envisioned that this system would provide time varying mechanical cues for
diﬀerentiation of stem/progenitor cells into adult cardiomyocytes and would also provide
mechanical conditioning to generate suﬃcient contractile forces and integrate within
native cardiac tissue to augment cardiac function. However, after re-examining carefully
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the working principles of this system, we recognized that the pressure-volume
relationships seen this in vitro system did not accurate replicate in vivo left ventricle PV
relations. First, in-vivo, the stretch of nature cardiac tissue is mainly due to the fluid
loading during the loading phase, while the stretch of the PDMS membrane in the
µCCCM is based on the pressure generated inside the cell chamber during the loading
phase. Second, the stretch and contract of cardiomyocytes are in 3D directions, which
include circumferential and radical stretch. With the post, this µCCCM system creates
the 2D biaxial stretching. In addition, in this model, the cells were seeded on a rigid 2D
surface membrane which potentially constrained cell shortening and does not reflect the
physiological condition of the in-vivo tissue.

The summaries of similarities and

differences between the left ventricle and the µCCCM system are listed on the table 3.1.
To overcome these shortcomings, the second generation of the cardiac cell culture model
(CCCM) was designed and developed. In this new system, cells were cultured on a soft
matrix attached to the top of a thin PDMS membrane in a cell culture chamber. With
each cycle, cells cultured within the CCCM underwent passive stretch, isovolumic
contraction and pressure buildup, ejection and relaxation. Thus, the second generation of
cardiac cell culture model system is essentially a left ventricle mimic that can be
dynamically tuned to go from static unloaded state (as seen in very early development),
to pulsatile pressure and cyclic stretch conditions seen in the adult heart.
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Table 3.1: Summary of similarities and differences (in italic) between the left ventricle
and the µCCCM system
Aspects
Working
principles

Circulation
network

Left Ventricle

The µCCCM system

-

“Filling” phase: fluid in, no
fluid out, no pressure buildup.

-

“Stretching” phase: fluid in, no
fluid out, low pressure buildup.

-

Isovolumic contraction phase:
pressure inside is compressed,
no fluid in nor out.

-

Contracting phase: pressure
inside is released, fluid in and
out.

-

Ejecting phase: cavity pressure
exceeds aortic pressure,
pressure peaks and then begins
to decline.

-

Ejecting phase: the releasing of
the collapsible valve- pressure
inside released and goes down.

-

Isovolumic relaxation phase:
muscle relaxes and pressure
decreases prior to the next
filling cycle.

-

Relaxing: similar to ejecting
phase

-

One way valves at the entrance and outlet of the ventricle

Stretching

-

3 dimensional strains

-

Cell
cultured

-

Soft tissue

-
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Only one collapsible valve
downstream of the chamber,
and the fluid continuously
loaded to the cell chamber.
Biaxial stretch
Hard surface

CHAPTER 4
THE SECOND GENERATION CCCM SYSTEM

4.1. COMPONENTS OF THE SECOND GENERATION CCCM SYSTEM
The Second Generation CCCM system consists of a fluidic flow pathway, an air
pathway, a cell culture platform station, and a control system (Fig. 4.1).122

The fluid flow network includes a medium reservoir, a peristaltic pump, a fluid
compliance, an upstream one-way valve, a cell culture platform station, a downstream
one-way valve, and a tunable pressure relief valve in a series (Fig.4.1). From the medium
reservoir, via the assistance of the pump, the fluid flows through the upstream one-way
valve into the cell culture chamber and exits the cell culture chamber. The fluid then
passes through the downstream one-way valve and the tunable valve and then returns
back to the reservoir before being recycled within this flow loop via the peristaltic pump.
A bypass with a spring valve was installed at the downstream pathway to prevent the
chamber pressure from exceeding the pressure range set up for each case of studies.

While the fluid network is a closed pathway, the air network is a partially closed
pathway. The air network includes the cell culture platform station, an air-compliance, a
pneumatic valve, and a pneumatic pressure driver (Fig. 4.1). Air from the driver enters
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the cell culture platform station and passes through the air compliance and the pneumatic
valve before returning to the pneumatic pressure driver.

This air network is a partial

closed network because the pneumatic valve is a three-way valve. One of its three ports
releases air to the outside when needed.
[A]

Pulsatile Pump

Reservoir

Fluid Pathway
Compliance

Tunable
valve
One-way
valve

Spring Valve

One-way
Valve

Cell Culture Chamber

Air Pathway

Air Compliance

Pressure
Sensor
Computer
LabView

Pneumatic Valve

Pressure Generator

[B]

Air Pathway

Figure 4.1: A schematic image of the second generation CCCM system. [A] 2 pathways
are described: fluid pathway and air pressure pathway. [B] Picture of the CCCM system
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where (a) the peristaltic pump, (b) upstream one-way valve, (c) the CCCM platform with
cell culture chamber (arrow) and (d) the downstream one- way valve.

The cell culture platform station includes a cell culture chamber, an oil chamber, and the
housing station (Fig. 4.2). The cell culture and oil chambers are placed on top of each
other and in between the top and bottom plates of the housing station. Cells are cultured
on a thin flexible PDMS membrane, which forms the base of the cell culture chamber and
is thus sandwiched between the cell culture and oil chambers. This cell culture membrane
deforms as fluid is loaded and unloaded to the chamber, applying cyclic stretch and
relaxation to the cells. Underneath of the oil chamber is a post membrane. Therefore, the
cell culture system is a chamber-membrane-chamber-membrane stack (Fig. 4.2.C). The
oil chamber transfers the displacement between the cell culture membrane and the post
membrane (Fig. 4.2.E). The post membrane prevents the cell culture membrane from
moving beyond its original position when the pneumatic pressure is applied on the other
side of the post membrane (Fig. 4.2F). Finally, the housing station has top and bottom
plates to sandwich the cell culture and oil chambers and to install the fluid and air
networks. The top plate of the housing station has an inlet and outlet ports for fluid
loaded and unloaded to the cell culture chamber while the bottom plate has the inlet and
outlet ports for the air from the air pathway in and out of the station.
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[A]

[B]

[C]

(v)

[D]

[F]

[F]

Figure 4.2: Scheme of the CCCM cell culture platform station. [A]: the housing station
has (a) top plate with fluid inlet (solid arrow) and outlet (breakdown arrow) and (b)
bottom plate with air inlet (solid arrow) and outlet (breakdown arrow).

[B]: the

assembled CCCM chambers. The assembled CCCM is sandwiched between plates of the
station. [C]: the components of the assembled CCCM chambers: (i) cell culture chamber,
(i) a flexible membrane where the cells are seeded (blue), (iii) oil chamber, and (iv) the
post membrane. The assembled CCCM system is a chamber-membrane-chambermembrane stack. [D] Side view of the CCCM cell culture station: (i) top plate with fluid
inlet (solid arrow) and outlet (breakdown arrow); (ii) cell culture chamber; (iii) cell
membrane (orange); (iv) oil chamber made by 3 components (top, middle, and
bottom)and filled with oil, and (v) the post membrane (black color) bottom plate with air
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inlet and outlet. [E] The scheme of membrane deformed when fluid is loaded to the cell
chamber. This case, oil in the oil chamber transfers the displacement between the cell
culture membrane and the post membrane, pushing the post membrane down (breakdown
bar). [F] Cell membrane goes back to its original position when the pneumatic pressure
is applied on the other side of the post membrane. Due to the block from the bottom
component of the oil chamber, the post membrane cannot move up further than its
original position, preventing the cell culture membrane from moving beyond its original
position.

Fluid flows into the cell chamber, deforming the membrane downward. The pressure
driver provides cyclic pressure on the other side of the post membrane, pushing the
deformed polymer membrane back to its original position.

Releasing this pressure

stretches down the cell culture membrane during the fluid loading phase (Fig. 4.3). The
frequency of this pressure as well as the percentage of loaded and unloaded time per each
cycle is controlled by the program set in the pressure driver.

Figure 4.3: Scheme of the PDMS membrane deflection under the influence of fluid and
pneumatic pressure loading and unloading. [1, lower left] PDMS membrane in the phase
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where no fluid filled into the cell culture chamber, the membrane has a horizontal
position with no stretch. [2, lower right] the membrane deforms downward when fluid
flows into the chamber from above (arrows down), [3, upper right] the membrane is
pushed back to its original horizontal position when outside pressure applied to the
inferior side of the post membrane, pushing the cell membrane up (arrows up); and [4,
upper left] after ejection occurs the membrane is returned to its original position and one
cycle of stretching-relaxing is completed.

The volume of the fluid loaded to the cell chamber is controlled by the peristaltic pump.
Cyclic pressure inside the cell culture chamber is generated via the tunable pressure
release valve and the pneumatic pressure inserted on the other side of the post membrane.
The frequency and the air pressure loaded and unloaded to the station are controlled by
the pressure generator. Finally, a pressure sensor connected to the cell culture chamber is
monitored via real-time LabView program; and the pressure waveform inside the cell
culture is hence recorded (Fig.4.4).
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Figure 4.4: Image of the CCCM system connected to the LabView control system via
pressure sensor.
4.2.

DESIGN AND FABRICATION OF DIFFERENT COMPONENTS OF THE

CCCM SYSTEM
4.2.1. Design the Top and Bottom Plates of Cell Culture Housing Station
The cell culture station was made in the Rapid Prototyping Facility at the University of
Louisville using the Computer Numerical Control (CNC) Milling Machine. The designs
were laid out using SolidWorks software prior to machining the assembly using CNC
milling. Acrylic was the material used for construction.

This station consists of the top and bottom rectangular plates (10.5 cm x 9.0 cm x 1.3 cm)
(Fig. 4.5). Two channels in the top plate serve as the entry and exit ports for fluid
loading and unloading to the cell culture chamber. The distance between two inner ends
of these channels is 0.6cm. The bottom plate of the platform has a circular hole (d =1.6
cm, h = 1.0 cm) at the center and 2 horizontal passages from the center hole to the outside
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edges (l = 4.6 cm, d = 0.4 cm), creating the inlet and outlet air channels. Finally, 4 holes
were drilled at 4 corners of these components for screw insertion.
[A]

Entry and exit ports

1.3 cm

[B]

1.3 cm

Figure 4.5: Schematic of the top and bottom plates of the station for housing the cell
culture chamber. [A] the top plate of the platform with entry and exit ports for fluid
loading and unloading; and [B] the bottom plate of the platform with a circular hole at the
center and two horizontal passages for pneumatic pressure pathway.

4.2.2. Fabrication of the thin PDMS membrane
The thin PDMS membrane was made from Sylgard®184 polydimethyl siloxane (PDMS)
(Dow Corning, Midland, MI) using standard soft-lithography techniques. First of all, a
mixture of silicon elastomeric base with its curing agent (ratio 10:1) was well mixed,
followed by a 15 minute vacuum to remove air bubbles created during the mixing
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process. To make a thin PDMS membrane less than 400µm thick, spinning method was
used and the thickness of the membrane was determined by the spinning speed and time
(Fig. 4.6). The degassed PDMS mixture was poured on a non-oxidized silicon wafer
(0.525 mm thick, 100 mm diameter, Silicon Valley Microelectronics, Inc. Santa Clara,
CA) and spun at a desire speed for 30 sec on a Headway Spinner (Brewer Science, Inc.,
Rolla, MO). The PDMS coated wafer was then baked at 90oC in an oven (Fisher
Isotemp, Florence, KY) for at least 1 h. Once the PDMS was cured, the wafer was
removed from the incubator. This method was used to make the post membrane.

Membrane Thickness (µm)

500
400
y = 130728x-1.05
R² = 0.9999

300
200
100
0

0

1000

2000
3000
Spinning Speed (rpm)

4000

5000

Figure 4.6: Graph of PDMS membrane thickness (µm) versus spinning speed (rpm).
The spinning time is 30 sec. The membrane thickness as a function of spinning speed
can be estimated using the equation y= 130728 x-1.05.
For the PDMS membrane thicker than 400µm, gasket method was used. Basically, the
degased PDMS was poured to a square gasket (13.0 cm x 13.0 cm outside and 12.0 cm x
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12.0 cm inside) sitting on a square glass (13.0 cm x 13.0 cm). The thickness of the gasket
determines the membrane thickness. A thin transparent plastic sheet was then slowly
placed on top of the PDMS mixture followed by another square glass. The whole setup
was clamped tightly with paper clips and was put in the 90oC oven (Fisher Isotemp,
Florence, KY) for being cured overnight to form a thin PDMS sheet (Fig. 4.7.). This
method was applied to create the PDMS membrane at the bottom of cell culture chamber.

Figure 4.7: Fabrication steps of making a thin PDMS membrane via the gasket method.
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4.2.3. Cell culture chamber and medium reservoir
For the cell culture chamber, the degassed PDMS mixture (10:1 ratio) was poured in a
mold until it reached 1.0 cm high. After being cured at 90oC in the oven, the molded
PDMS was removed from the container and a square piece of PDMS (3.0 cm x 3.0 cm x
1.0 cm) was cut (Fig. 4.8). A hole (d = 1.4 cm) was punched at the center of this PDMS
piece using a cork borer. Finally, a thin PDMS cell membrane, which was previously
made, was placed at the bottom of this PDMS to form the cell culture chamber.

To provide medium for cells cultured before placing them to the CCCM system, a
medium reservoir was also created. A hollow PDMS square piece (2.5 cm x 2.5 cm
outside and 2.0 cm x 2.0 cm inside) was cut from the molded PDMS (Fig.4.8). This
reservoir was then placed on top of the cell culture chamber before sterilization.

Figure 4.8: Fabrication steps involved in construction of the cell chamber and the
medium reservoir.
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To measure the pressure inside the cell culture chamber, an accessible pressure chamber
was created. The molded PDMS slack was cut (3cm x3 cm) and a center hole was
punched, similar to the cell culture chamber. A horizontal channel was then created from
the center hole to the edge via an 18 gauge blunt syringe needle (SmallParts, NE181PLC). Finally, a 24 gauge blunt syringe needle (SmallParts) was inserted to this horizontal
channel, served as a connecting port for the pressure sensor (Fig. 4.9.).

Figure 4.9: Schematic representation of fabrication steps involved in construction of the
assessable pressure chamber.
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4.2.4. Oil chamber

The oil chamber was built in a mechanical shop Facility at the University of Louisville.
Three square acrylic pieces were cut and a circular hole was grilled at the center of each
piece. The dimensions of each squares acrylic pieces were in the table 4.1 below. The
edges of these pieces were smoothed before these pieces were glued together respectively
to form the oil chamber. (Fig. 4.10, left)
Table 4.1: Dimensions of each component of the oil chamber
Components

Thickness

Square dimensions

Hole diameter

Top component (i)

0.3 cm

4.0 cm x 4.0 cm

1.3 cm

Middle component (ii)

1.0 cm

4.0 cm x 4.0 cm

2.5 cm

Bottom component (iii)

0.3 cm

4.0 cm x 4.0 cm

2.0 cm

(i)
(ii)
(iii)

[B]
[A]
Figure 4.10: Schematic images of the oil chamber. [A] The oil chamber (top) and the
post membrane (bottom). [B] Side view of the oil chamber: top component (i), middle
component (ii), bottom component (iii) and the post membrane (black). Oil chamber is
filled with oil. PDMS cell culture membrane (dark blue) is placed directly on the top of
the component (i).
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4.2.5. Fabrication of the post membrane
A thin 400 µm PDMS (4.0 cm x 4.0 cm) previously made on a silicon wafer was peeled
off. This thin PDMS membrane and a circular glass (d = 2.5 cm, t = 0.25 cm) were
exposed to 10% oxygen plasma for 30 sec in a reactive ion etcher system (RIE March
Instruments) with 150 mmTorr and 150 mmHg. The membrane and circular glass were
then bonded together centrically and irreversibly to form the post membrane (Fig.4.11.).
Finally, the subject was heated at 115oC on a hotplate (Standard Model 1100 Hotplate,
Brewer Science, Inc., Rolla, MO) for 10 min to enhance the quality of bonding.

Figure 4.11: Schematic representation of fabrication steps involved in construction of
the post membrane.
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4.3. ASSEMBLY OF THE WHOLE CCCM SYSTEM
4.3.1. Assembly of the cell culture platform
The cell culture platform was assembled in a sandwich style.

In general, the post

membrane, oil chamber, cell culture chamber, and pressure chamber were stacked on top
of each other respectively and clamped between two fixtures of the apparatus. In detail,
first of all, the oil chamber was firmly laid on the top of the post membrane to form a
unit; and oil was used to fill this oil chamber. Secondly, after the reservoir on the top of
cell chamber was removed, the accessible pressure chamber was placed on top of the cell
culture chamber to form cell chamber unit. This unit was then placed centrically on top
of the oil chamber without creating air bubble inside the oil chamber.

Thirdly, these

stacked membranes-chambers were placed on top of the bottom component followed by
the top fixture. Finally, screws were used to tighten the components. (Fig. 4.12)

Top component
Oil chamber with
the post membrane

Cell culture chamber
with pressure chamber

Figure 4.12: Side view of the whole assembled CCCM platform.

Bottom
component

4.3.2. Connection of the cell culture platform to the CCCM system
The assembled cardiac culture platform was then connected to the flow loop and cyclic
pressure network as shown on Fig. 4.2. First, a 50 mL tube served as the medium
reservoir to supply fluid to the cell chamber and to receive fluid flowing back from the
cell culture chamber via a peristaltic pump, ensuring a continuous supply.

Fluid

compliance and a one-way valve were connected to the upstream of the fluid flow
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network. A one-way downstream valve, tunable valve, and a by-pass pathway with a
pressure gate valve were installed at the down-stream of this flow loop.

Flexible,

autoclave compatible polymeric tubing was used to establish connections within the flow
loop (Fig.4.13). Second, the pressure sensor was attached to the cell culture chamber via
the needle port of the pressure chamber. Third, the air compliance was attached to the
apparatus.

This whole set up was then moved to the incubator before the pneumatic pathway was
connected to the platform. Once in the incubator, the air compliance was connected to
downstream of the pneumatic pathway, while upstream of the airway was hooded to a
pulsatile pneumatic pump (lb Engineering GbR).

Finally, the pressure sensor was

connected to the computer; and the pressure inside the cell culture chamber was
transferred digitally to the LabView Program on the computer.

Figure 4.13: Picture of the CCCM experimental setup.
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4.4. WORKING PRINCIPLES OF THE CCCM SYSTEM
The working cycle of the CCCM mimics the working cycle of the left ventricle (Fig.
4.14). In the filling phase, fluid flow is introduced continuously into the CCCM cell
culture chamber via the peristaltic pump. Fluid fills the cell culture chamber causing the
PDMS membrane to stretch passively. The stretching of the membrane maintains the
pressure inside the cell culture chamber as low as the base pressure should be. This
stretching phase mimics the left ventricular diastolic filling. During the isovolumic
contracting phase, air pressure generated by the pulsatile pneumatic pump (the frequency
and pressure are programed based on each specific experiment) is applied to the reverse
side of the post membrane, pushing the PDMS cell membrane back to its original
position.

Pressure is thus built up rapidly within the cell culture chamber, causing the

upstream one-way valve to close. Because of this valve closure, the fluid from the
peristaltic pump begins to be stored in the fluid compliance. However, the cell chamber
pressure at this point is not high enough to overcome the downstream resistance,
therefore, no fluid is loaded or unloaded to the chamber. This phase is similar to the
isometric contracting phase inside the left ventricle. For the ejecting phase, the pressure
inside the cell chamber increasing until it exceeds the set value of the resistance to open
the downstream valve and then the accumulated fluid loaded in the cell culture is ejected.
Finally, the pressure applied to the reverse side of the membrane is released, causing the
CCCM to undergo isovolumic relaxation before another cycle begins. This phase mimics
the isometric relaxing phase of the left ventricle.
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[A]

[B]

Figure 4.14: A working cycle of the CCCM system and the pressure-volume loop
occurred in left ventricle of the heart. [A] Schematic working principles of the CCCM
system, including stretching phase (fluid loading causes the membrane stretched down),
contracting phase (pneumatic pressure applied to the other side of the membrane brings
the membrane back to the original position and elevates the chamber pressure), ejecting
phase (chamber pressure overcomes the downstream resistance to eject the fluid out of
the chamber), and the relaxing phase (no fluid in or out). X: valve is closed; : fluid
direction. [B] Pressure-Volume loop seen in the left ventricle: (a) diastolic filling phase,
(b) isovolumic contraction phase, (c) ejecting phase, and (d) isovolumic relaxation phase.

Additionally, a programmable pressure generator is used to supply periodic pulses of
pressurized air to the reverse side of the polymeric membrane on which cells are cultured
to mimic ventricular contraction. Finally two tunable compliance elements, a fluidic
compliance integrated prior to the upstream one-way valve, and air compliance element
integrated at the end of the pressure generator flow path, are used to modulate pressure
waveforms within the cell culture chamber. Therefore, with the pulsatile pneumatic
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pump, the frequency of the stretching-contracting of the PDMS cell culture membrane is
controlled; and the cylclic pressure inside the cell culture membrane is also generated,
similar to the cyclic pressure seen in the left ventricle.

4.5. OPERATION OF THE CCCM SYSTEM
The assembly of the CCCM system was performed inside the cell culture hood. Once the
CCCM platform station and the fluid network were assembled as in Fig. 4.13, the whole
set up system was moved into the cell incubator. Then, the peristaltic pump began to run,
followed by the connection of the air network to the pressure generator, which had been
on. Along with the controlling from the pressure generator, the downstream tunable
valve was adjusted until the pressure reached the desirable values. Variable parameters,
such as the frequency of the membrane stretching as well as the percentage of systolic
phase per one cycle, were determined based on the requirement of each experiment. The
frequency of the stretching was controlled through the systolic time and the frequency
control on the pressure generator source. The pressure inside the cell chamber was varied
depending on the pressure applied on the post membrane and the adjustment of the
tunable valve.

At the end of the experiment, peristaltic pump was turned off first

followed by the pressure generator. Finally, the cell chamber was removed from the
platform.

4.6. CONCLUSION
Recognizing the limitations of the 1st generation µCCCM model, the second generation
CCCM system was created to more accurately reproduce the mechanical loading and
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unloading conditions observed in the heart.

This system is capable of accurately

mimicking preload and afterload experienced in the healthy and failing heart.

The

CCCM allows for dynamic studies, accomplished via direct manipulation of flow rate,
valve operation, membrane thickness and the height of the cell culture chamber. When
working with different types of cardiac cells or different physiological heart conditions, it
is important to ensure that the type of mechanical loads delivered such as the stress,
stretching, frequency of stretching, and the shear stress can be dynamically controlled.
The following chapter therefore focusses on the characterization of this CCCM system.
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CHAPTER 5
CHARACTERIZATION OF THE CCCM SYSTEM

5.1. YOUNG’S MODULUS OF THE THIN PDMS MEMBRANE
5.1.1. Introduction of PDMS
Polydimethyl siloxane (PDMS) is a common silicon rubber used for various applications
such as mechanical interconnective layers between 2 wafers, mechanical-chemical
sensors, microvalves in fluid applications, and biomedical applications.123-125 PDMS
Sylgard 184 from Dow Corning Corporation (Midland, MI) is one of the two most
common silicone products. It contains a base polymer and curing agent. Cross-linking
reaction is the main reaction for the curing of PDMS; and this curing process is enhanced
via heating process.126 Therefore, the PDMS rigidity can be controlled by the ratio
between its base and cross-linking agent, the heating temperature and the time of baking.

PDMS is a substrate widely used for cell behavior studies due to several advantages.
PDMS is biocompatible, transparent, gas permeable, autoclavable, and elastic. This
silicone is also physically and chemically stable.127 It has a high flexibility and
compressibility, suitable to use for making a thin stretchable membrane in the CCCM
system. The fabrication of PDMS membrane is straight forward, less time consumed,
and cost effective, making it suitable for replication.125 PDMS is also hydrophobic; and
yet, via oxygen plasma treatment, it becomes hydrophilic for a few minutes before going
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back to its original hydrophobic state.126 This special chemical characteristic of PDMS
helps different PDMS layers bond to themselves and therefore creating a watertight seal
between layers of the CCCM culture chamber when the PDMS becomes hydrophobic.

In this project, Young’s modulus and strain value of the thin PDMS sheet used in the
CCCM system were determined.

Due to the fact that this thin PDMS membrane is an

elastomer and has the ability to hold a large amount of strain, true stress σ* and true strain
ε* were determined from the engineering stress σ and strain ε of the PDMS membrane.
Young’s modulus E of the thin PDMS membrane under the tensile force was obtained by
the following equations: 127, 128



F
A0

σ*= σ(1+ε)

and  

L
L0

and ε*= ln (1+ε)
E

*
*

(1)
(2)
(3)

where F is the tensile force applied onto the membrane, A0 is the original cross-sectional
area, ∆L is the elongation of the membrane after stretched, and L0 is the original length of
the membrane.

5.1.2. Tensile test
The RSA III Rheumatics System Analyzer was used for the PDMS tensile tests. First,
the fabricating method for the thin PDMS sheet was described from section 4.2. The
ratio of mixing between the base and curing agent was 10:1. The curing temperature was
set at 90oC and the baking time was from 12 h or overnight. After cured, this thin PDMS
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sheet was cut into strips (0.5 inch x 4.0 inches) and vertically mounted in the way that
one end of the strip was attached to a fixed fixture while the other end was clamped to a
movable fixture of the RSA Analyzer (Fig. 5.1). Zero force was initialized and the
tension force was applied. The membrane was pulled slowly with the rate of 0.5 mm/s
until it reached a 50% displacement (2 inches). Three different thicknesses of PDMS
membranes (250 µm, 400 µm, and 500 µm) were used. At least five different PDMS
pieces molded on different days with the same thickness were made for this tensile test.
The excel program was used to determine the stress, strain, and Young’s modulus of the
PDMS.

ΔL
L0

Figure 5.1: Experimental setup image for the strain and Young’s Modulus measurement
of PDMS membranes. Left: The PDMS strip (arrow) was installed between 2 fixtures of
the RSA Analyzer. Right: Sketch of the displacement of a thin PDMS strip.
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5.1.3. Results and Discussion
The mechanical properties and Young’s modulus of different PDMS thicknesses were
determined. Young’s modulus of the PDMS depends greatly on the stress-strain curve,
mixing ratio and strain rate.127 For consistency, the mixing ratio of 10:1 (base: curing
agent) was carried throughout this project. Tensile tests on the PDMS membrane were
conducted. During the testing process, the elongation of the strips and the tensile forces
were recorded automatically by the system. By loading the dimensions of the PDMS
strip to the system, the engineering stress and the engineering strain were obtained. Since
the PDMS is an elastomer and has a capacity to hold a large amount of strain, the true
stress and true strain derived from engineering strain were used to calculate the elastic
modulus of the PDMS (Fig. 5.2.) The results shows that with the PDMS thickness from
250 µm to 500 µm, Young’s modulus and stress-strain relationship were not significantly
different among each membrane thickness. The Young’s modulus of the thin PDMS
membrane was calculated using the equation (3) in the section 5.1.1, which was around
1.0 ± 0.17 MPa. The graph of stress vs strain and Young’s modulus value agree with the
results obtained from other research groups.126-128 These results were helpful to assist the
fabrication of various membranes with different thicknesses for cardiac culture. Amongst
these three membrane thicknesses, membrane with the thickness of 500 µm was used for
cardiac tissue cultured in the CCCM system later.
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Figure 5.2: Graphs of stress versus strain of thin PDMS sheets

5.2. PRESSURE GENERATED INSIDE THE CCCM CELL CHAMBER
A synergistic relationship exists between the pump flow rate, membrane thickness, downstream resistances and the magnitude of pressure pulses within the CCCM. All these
parameters need to be set precisely to ensure proper filling and ejection of fluid from the
cell culture chamber and mechanical stresses. The pressure waveform generated from the
CCCM cell culture chamber was determined by the pressure input from the pulsatile
pneumatic pump, frequency, flow, percentage between the stretching and contracting
phases of each cycle as well as the downstream resistance. These variable parameters
were determined and adjusted based on the requirement of each experiment.

The

frequency of the stretching was controlled by the frequency set up on the pressure
generator. The pressure inside the cell chamber was mainly varied by the cyclic pressure
applied on the post membrane and the adjustment of the tunable valve. For the proof of
concept, the profile of pressure wave forms for different human heart conditions (normal,
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hypertension, hypotension, heart failure, bradycardia, and tachycardia)111 seen in the left
ventricle of human heart were generated inside the cell culture chamber of the CCCM
system. (Table 5.1 and Fig.5.3.) This accomplishment indicates that this CCCM system
can be a benefit for in-vitro cardiomyocyte studies under the effect of physiological
mechanical relevance of different heart conditions.

Table 5.1: Hemodynamic parameters corresponding to the left ventricular mechanical
loading during various clinical conditions were replicated using the CCCM system.
These parameters include heart rate, systole as percent of the cardiac cycle, end systolic
pressure, and end diastolic pressure of the left ventricle were applied to the CCCM
system to obtain the pressure waveforms in the following figure 5.3 below. LV (left
ventricle).
Conditions

Heart Rate
(bpm)

Systolic
Fraction
(%)

LV systolic
pressure
(mmHg)

LV end diastolic
pressure
(mmHg)

Normal

75

40

125

9

Hypertension

75

40

183

6

Hypotension

75

40

95

6

Heart Failure

75

40

100

27

Tachycardia

200

50

120

4

Bradycardia

46

40

124

8
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5
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Figure 5.3: Pressure vs time plots representing the changes in pressure within the
CCCM cell culture chamber for different human heart conditions. The parameter of the
pressure and frequency were determined based on different conditions seen in the left
ventricle of the human heart.
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5.3. STRAIN OF THE PDMS CELL CULTURE MEMBRANE
As the cell type changed from H9C2 cells to embryonic chick ventricular cardiomyocytes
as the primary cell line for characterization of the CCCM chamber, we set the CCCM
strain to replicate the strain of the in-vivo chick embryonic left ventricle cardiomyocytes
at stage of 36; which is reported to range from 0.10 to 0.20.

129, 130

For in-vitro CCCM

culturing, strains of 8-15% were applied.

When fluid was induced to the cell culture chamber, PDMS experienced both radial and
circumferential stretches (Fig. 5.4). These stretches of the PDMS membrane were also
conveyed to the cells seeded on that membrane. Both strains were determined via the
simulation from the ANSYS software program as well as via experimental membrane
deflecting movies obtain from a Ultra Sound system.

Figure 5.4: Scheme for the stretches of the circular membrane

5.3.1. Membrane Deflection Strain measurement via ANSYS program
The following formulas were used for calculation:
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 Mooney- Rivlin strain energy (5 parameters) for hyper-elastic material (PDMS)
Ψ= C10(T1-3)+C01(T2-3)+C11(T1-3)(T2-3)+C20(T1-3)2+C02(T2-3)2+(1/d)(J-1)2

(4)

C10,C01,C20,C11,C02 = material constants
d = material incompressibility parameter
T1 ,T2, T3 = invariants of the right Cauchy-Green deformation tensor
 Volume:
(5)
V: volume; R: radius; and h: height

 Radial strain

:
(6)

Rf and Ri: final and initial radius of the membrane (Fig. 5.5)
 Circumferential strain

(Green strain equation):
= 0.5(λc2-1)

(7a)

λc=(2πrf )/(2πri )

(7b)

λc: circumferential stretching ratio; rf and ri: final and initial radius at horizontal
position

Instead of using fluid flow model to create the membrane deformed, different pressure
scales were applied. In this perspective, it was assumed that for a small amount of fluid
loaded to the cell chamber, the shape of the extending PDMS was similar to the semisphere.

In this case, 44µl fluid was applied for 1.3cm diameter membrane. This value
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was selected based on the condition of the experiment for the embryonic chick ventricle
cell culture that was performed later in chapter 6. From equation 5, the maximum
deflection (or height) was estimated. This maximum deflection value (h = 0.33mm) was
used as a reference for the deflection profile of the cell membrane generated by the finite
element analysis (FEA).

Finite element software ANSYS 14.5 (Southpointe, PA) was utilized to generate the
membrane deflecting profile as a function of applied pressures. The PDMS membrane
was modeled using SHELL 281 with 2D, axi-symmetric boundary condition. For this
simulation, it was assumed that PDMS membrane was hyper-elastic material; therefore,
Mooney-Rivlin strain energy was used to declare the physical properties of PDMS
membrane,122 and large deflection mode was turned on. The thickness of the membrane
was 500 µm and a Poisson’s ratio was 0.49. The membrane was assigned with fixed
boundary conditions at the edges, and the pressure was applied evenly on the top of the
membrane. For each run, a certain pressure value was applied to the membrane until the
maximum deflection of the membrane (h ~ 0.33mm) was obtained. Once the
displacement profile (Fig. 5.6) was obtained, the radial and circumferential strains of the
membrane were determined (Fig. 5.7). The radial strain from the center to the edge was
estimated using Eq. 6 and 7, where Rf and Ri are the initial and final radius.
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Figure 5.5: Schematic demonstration for radial strain (left) and circumferential strain
(right) measurements for a thin PDMS circular membrane.

Displacement (mm)
Figure 5.6: The sketch of PDMS membrane deflection (d = 13.0 mm, t = 0.5 mm) using
SHELL 281. The maximal displacement of this membrane was 0.33 mm at the center.
79

Membrane Deflection (mm)

[A]

Radial Location (mm)

[B]

14
12

% Strain

10
8
6
4
2
0

-8

-6

-4

-2

0

2

4

6

8

Radial Location (mm)

Figure 5.7: Plots of displacement and strain of the circular PDMS membrane. [A] Plot
of the PDMS membrane displacement from ANSYS and [B] Estimation of radial strain
(▲) and circumferential strain (■) on the thin polymeric membrane at the bottom of the
cell culture chamber as a function of radial position.
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5.3.2. Strain measurement via real set-up experiment
Besides using Finite Element Analysis (FEA) to estimate the membrane deflection and
strain

122

, we used high resolution ultrasound Imaging (Vevo-2100, Visual Sonics Inc,

Toronto, Canada) to examine the membrane displacement of the real set-up system. A
MS-400 probe (30 MHz) was used for recording the cyclic movement of the membrane
(Fig.5.8.).

[A]

[B]

[1]

[2]

Figure 5.8: Images of experimental set up for taking real-time video of the PDMS
membrane deflections using the Ultra Sound system. [A] Image of the Vevo2100 high
frequency ultrasound system used for the PDMS strain measurement. [B] Experimental
set-up for the strain measurement with [1] probe and [2] CCCM platform where the
CCCM culture chamber was installed.

Three different experiments were set up with three different 500 µm thick PDMS
membranes. The flow rate was set at 44µl/cycle, the cyclic pressure was from 0mmHg as
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the base to its peak of 10mmHg, and the frequency was set at 2.0 Hz with 40% diastolic
phase. To ensure that CCCM system worked correctly and the membrane deflection was
in the right range for each membrane, manual ejections of different fluid volumes (25 µl
and 50 µl) were performed besides the real set-up experiment (Fig. 5.9.).

Figure 5.9: Ultrasound images of PDMS membrane deflection at 0, 25, and 50 µl fluid
loading along with the real set-up experiement.

From these images, the level of

membrane stretch from the experiment is located between 25µl and 50µl injections.

For each ultrasound movie, the deflecting movement of the PDMS membrane was
converted to single moving slides (30 slides /sec). The base slide and the maximum
deflecting slides were selected for each measurement (Fig.5.10.).

Using an ad hoc

program developed in MATLAB (Mathworks, Natick, MA), reference points and
displacement points along the membranes from the base line and the maximum deflecting
slides were created evenly along the membrane to determine the Ri and Rf.

The

deflection profile was then created to calculate the strains, and the radial, as well as the
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circumferential strain of these membranes, were therefore calculated using the equations
(6) and (7a-b).

5.3.3. Conclusion
In addition to the pressure stimulation, stretch levels in cardiac cells play a critical role
ensuring cell phenotype and function. In the CCCM system, cardiac cells were attached
and grown on a soft matrix which is laid on the thin PDMS membrane. Therefore, the %
strain of the PDMS membrane represents the stretch level of the cells growing on it.
With two different methods for strain measurement, the strain profile for the PDMS
membranes was found to match the strain experienced by cardiomyocytes within the
native ventricle. These results confirm that the PDMS membrane could replicate in-vivo
stretch experienced in the heart.

83

[A]

[B]

[C]

[D]

-8

20

Radial Strain (%)

Circumferential Strain (%)

20

10

-4

0

0

4

8

Radial Location (mm)
50 µl

experiment

-8

10

-4

0

4

8

Radial Location (mm)

50 µl

25 µl

0

experiment

25 µl

Figure 5.10: Results of the PDMS membrane deflection. [A] Slide of base line where no
fluid was loaded to the system. [B] Slide of the maximum PDMS membrane deflection.
The vertical lines were created to divide the membrane in even distances between 2
edges. [C] Image of reference points on the base line (green color) and displacement
points along with the deflecting curve (blue color). [D] Graphs of circumferential strain
(left) and radial strain (right) of the 500µm PDMS membrane.
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5.4. SHEAR STRESS MODELING
The dimension of the cell culture well is similar to the dimension of the previous
µCCCM model. The height of the later model is 0.5cm higher than the height of the well
in the µCCCM model. Therefore, a design guideline published in the prior work (for the
µCCCM system111) was applied to ensure that the depth of the cell culture wells was
>0.5 cm, resulting in low shear recirculation at the bottom of the wells. This work was
performed by Vahidreza Parichehreh, the co-author of the previously published
manuscript.111 Below is the detail copy of method and results from the previous work for
shear stress modeling in the µCCCM system.
5.4.1. Method
Finite element software ANSYS Academic Teaching Advanced 12.0, FLOTRON
module, was used to determine the wall shears stress as a function of channel height and
flow rate.

A 2D simulation was applied and environment was verified for steady

incompressible flows. For the simulation, it was assumed that no-slip boundary
conditions for the channel and groove walls, and that the participating fluid has the same
physical properties of water with the density of 1000 kg.m-3 and the dynamic viscosity of
10 Pa.s. The inlet fluid flow rate was set at 8.6 mL/min and zero pressure was applied to
the outlet. The fluid domain was meshed using 2D quadrilateral element, FLUID141, to
model steady state fluid. A segregated sequential solver algorithm was used; that is, the
matrix system derived from the finite element discretization of the governing equation for
each degree of freedom was solved separately. The mesh was refined through mesh
sensitivity analyses: at each simulation, the elements showing high velocity gradients
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were refined, until reaching convergence of sensitive measures of the predicted
quantities.

5.4.2. Results
Four wells with different depth (0.25, 2.00, 4.00, and 8.00 mm) were used; and a velocity
of ~ 0.024 m/s (corresponding to 8.6 mL/min) at the inlet of the wells was applied in all
the experiments. The shear stress (τ) was determined using the equation 131
 

du
dy

where τ is the shear stress(dynes/cm2), µ is viscosity coefficient (kg/(m.s)), u is the fluid
velocity (m/s). The viscosity (µ) of water at 1atm and 20o C is 1.0 x 10-3 kg /(m.s).131
5.4.3.

Discussion

The flow velocity simulation (Fig.5.11.) showed that for the wells with depth of 2.00,
4.00, and 8.00 mm, with the flow rate of 8.6 mL/min, the flow velocity was nearly 0.00
m/s at the bottom of the well whose height is higher than 0.25mm. Indeed, the result
from ANSYS shows that the shear stress was 0.00 dynes/cm2 to approximately 200 µm
above the bottom of the wells with the height higher than 8.0 mm. The second generation
CCCM system has the same diameter of cell chamber and same dimensions of fluid inlet
and outlet; but the height of the chamber is about 10.00 mm. With this height, definitely,
fluid flow will not create a significant shear stress, affirming that cell cultured in the
second generation CCCM won’t expose to the shear stress.

In addition, this

characterization confirmed that this system can be able to manipulate the shear stress
based on the height of the cell chamber and the velocity of the fluid.
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Figure 5.11: Flow velocity simulation for the cell culture chamber of the µCCCM. Note
that the flow velocity are almost 0.00 m/s at the bottom of the wells except the 0.25mm
deep well, meaning fluid movement does not touch the bottom of these wells; therefore,
shear stress is negligible at the bottom region where cells are cultured.

5.5. CONCLUSION
Overall, the characterization of mechanical properties of thin PDMS membrane and
pressure, strain, and shear stress affirmed strongly that the CCCM can be used to
replicate the in vivo heart function. This replication can be accomplished through a
combination of different variables such as membrane thickness, the height of the cell
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chamber and adjustment of tunable components, including the tunable valve, the
peristaltic pump, and the pressure generator.
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CHAPTER 6
USING THE CCCM SYSTEM FOR CARDIOMYOCYTES STUDIES

6.1. BUILDING THE EXTRACELLULAR MATRIX FOR CARDIAC CELL
CULTURE
6.1.1 Introduction
The development of scaffolds that mimic the in-vivo extra cellular matrix (ECM) is
crucial for the engineering tissue remodeling/regeneration. The ECM provides a
microenvironment for cells to grow, proliferate, and migrate.

The biochemical,

structural, and mechanical properties of scaffolds play a significant role in regulating cell
adhesion to ECM and to neighboring cells, which in turn affect cell morphogenesis and
differentiation.132-137 It is true especially in the case of in-vitro cardiomyocyte studies,
the beating rate, force of contraction, and cytoskeleton structure of cardiac myocytes
which depend greatly on the ECM.132,

133, 138, 139

Therefore, cardiac cells need to be

seeded and grow on a soft cell culture matrix, similar to the in-vivo heart tissue. In this
study, collagen matrix was used. Based on the paper published,16, 140 the cell culture
matrix used for cardiac tissue was determined via the morphology and spreading of cells
similar to the in-vivo physiology. Therefore, the concentration of the collagen used for
constructing matrix was 0.667g/ml collagen.16, 140
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In addition, to ensure that the collagen ECM was not rapidly digested by the
cardiomyocytes during the experiment, crosslinking with glutaraldehyde was applied to
the matrix. Glutaraldehyde is a cross-linking agent that is commonly used for collagenbased biomaterial.141,

142

Finally, for the cell to attach and grow on the cross-linked

collagen ECM, a gelatin solution containing fibronectin was also added to the matrix
prior to the cells seeded.

6.1.2. Fabrication of the ECM
First, the sterilized PDMS cell culture chamber was treated with oxygen plasma to create
a hydrophilic surface (March RIE, 200 mmTorr, 200 mmHg, 10% oxygen, 30 seconds).
Then, a 300 μL of the collagen type I solution (0.67 mg/mL) was promptly added to the
cell culture chamber and allowed to be cured at 37°C for 3-4 h. Second, a 400 μL of
0.5% (w/v) glutaraldehyde solution was gently added on the surface of the cured collagen
matrix and maintained for 1 h at room temperature (RT). After 1 h, the matrix was
washed with deionized (DI) water three times, followed by a 4N sodium hydroxide
solution twice (30 min/each). Finally, DI water was used again for the final wash (three
times). The cell chamber was filled with DI water and stored at 4 °C for later use. 48 h
before cells were seeded, a 400 μL solution composed of 10% gelatin attachment factor
(1X, Gibco, S- 006-100) and 50 μg/mL of fibronectin (BD Biosciences, 356008) was
added to the chamber. A one-time washing with 1X PBS or fresh culture medium was
performed before the cells were seeded.
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Figure 6.1: Image of the collagen matrix with cardiac cells after 4 day cultured in the
CCCM system.

6.2. CULTURING CARDIOMYOCYTES IN THE CCCM SYSTEM
6.2.1. Primary embryonic chick ventricular cardiomyocytes
Embryonic chick cardiac cells are commonly used to study the complex processes
leading to normal or abnormal heart development. Chick embryonic heart development
is quite similar to that of the human heart. Fertile chick eggs are relatively easy to obtain
and less expensive than rodent models. Finally, it is possible to observe the embryonic
heart at the earliest stage of its embryogenesis and to isolate embryonic cardiomyocytes
for in-vitro culture.15, 79, 143

During the embryonic period, cardiomyocytes have a high proliferation rate and
differentiation.16 The synthesis of DNA from the embryonic cardiomyocytes reaches its
peak during the cardiac morphogenesis. During this developmental window, mechanical
hemodynamic loading and unloading play a crucial role in regulating the cardiomyocyte
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morphogenesis, architecture, and contractile functions and stimulating different
molecular signal pathways.

On the other hand, in response to these mechanical

stimulations, embryonic cardiomyocytes themselves regulate their proliferation and
differentiation rate. Therefore, any changes in mechanical hemodynamic loading and
unloading system affect the development of cardiomyocyte tissues and their contractive
functions greatly.

Chick embryonic heart development can be divided into 46 stages, called Hamburger
Hamilton (HH) stages.79,

144

These stages are used rather than only using days of

incubation due to variations in maturational rate that occur in response to changes in
ambient environmental factors. The first myocardial differentiations are detected on
stage HH7 when the formation of the endocardial heart tube begins. On HH 8, the
process of heart tube fusion starts, and is completed on HH 11. Heart beat begins on this
11th HH stage. During stages between the 13 to the 18, the heart tube transforms to the C
shape loop then to the S-shape loop to form atria and ventricles. HH 18-22, the primary
ventricular channels can be observed. HH 21-34, valve development, vasculature, atrial
and ventricular septations are gradually formed, along with other cardiac components,
such as the cardiac conduction system, atrial-ventricular (AV) nodes or cardiac neural
crest. Ventricular septation is completed around HH 34. HH 36 (or day 10 gestation),
the Purkinje fiber network begins to form and the atrial-ventricle valve is completely
formed to separate the atria from the ventricle. HH 40-41 is the hatching stage. Besides
the HH stage, the stages of embryonic heart development can also be named based the
incubation day. The chick hatches on approximately the 21st day of incubation. Primary
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cardiac morphogenesis occurs between day 2 to day 10 of a 21-day gestation. Day 10 is
corresponding with HH36, where the ventricles are completely separated. Therefore, we
selected 10th day embryonic chick ventricles for cell isolation in our CCCM experiments.

Embryonic cardiac development depends on the integration of the environmental
conditions, biomechanical forces, molecular programming, and adaptive remodeling.
Cyclic mechanical stimulation inside the heart induces myocardial hyperplasia.

In

addition, in the early period of cardiac morphology, the function of chick embryonic
cells, including the adaption of the contractile function, is greatly affected by mechanical
loading conditions. Mechanical stimulation thus affects the formation of the shape, as
well as the growth of heart chambers. Indeed, applying mechanical stimulation during
different stages of the embryonic period will greatly affect the function of the heart
tissue, which includes cell proliferation, contraction, frequency, and the duration of
contraction. Heart cells start beating synchronically and strongly, similar to the in-vivo
nature, reached the peak in-vitro on culture day 12.16 Therefore, the heart embryonic
tissue increased active contractile force from culture day 7 to day 12. Also, culture day
12 has the highest proliferation. However, the contractile response to the β-adrenergic
stimulation was less than culture day 9. Under these studies, 3 different developing
stages were standardized for mechanical stimulation: from culture day 4 to 6 (before the
cells increase the contraction force), from culture day 9-11 (before the proliferation goes
down), and at culture day 13-15 (the transition between embryonic and fetal stages).

93

6.2.2. Embryonic chick cardiomyocyte isolation and culturing
6.2.2.1. Embryonic Chick Cardiomyocyte Isolation and seeding
Fertile White Leghorn chicken eggs (Utah) were incubated in a forced-draft, constanthumidity incubator until day 10 of the gestation (HH: stage 36).

Ventricles were

collected and enzymatically digested using 2 mg/mL of collagenase type II, followed by
0.05% trypsin-EDTA solution (Invitrogen, Carlsbad, CA). The cell solution was then
filtered and isolated cells were collected. An 1 h pre-plate for the isolated cells at 37oC
was performed in 10 mL of cell culture medium (DMEM high glucose, 10% Fetal Bovine
Serum, 1% embryonic chick extract, and 1% antibiotic), followed by a 5 min centrifuge
at 1000rpm. Cell pellet was then re-suspended in a new 10 mL of cell culture medium
and were cultured on a gyratory shaker (60−70 rotations/min) for 18 h to re-aggregate
viable cardiomyocyte clusters. The following day, the whole cells, clusters, and medium
were collected and spun at 1000rpm for 5 min. Old medium was discarded and 1ml of
warmed fresh medium was added. Cell clusters were counted and cell viability was
checked with Trypan blue staining. For each cell culture chamber prepared from the
session 6.1.2, approximate 500µl of 3.0−3.5 × 104 cell clusters were seeded and cultured
in a static condition at 37 °C, 5% CO2 for 3 h before filling the reservoir with warmed
fresh culture medium. A static culture condition at 37oC and 5% CO2 was maintained for
24 h to obtain 100% confluence. On the following day, the sample was subject to
mechanical loading within the CCCM, or maintained under static conditions as a control.
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6.2.2.2. Culturing cardiac cells under the influence of mechanical stimulation within
the CCCM
Day 10 embryonic chick cardiomyocytes experience in-vivo peak pressures of ∼10−15
mmHg and radial and circumferential strains of ∼10−20%.130 Since the cardiac cell
tissue is thinner and weaker than the in-vivo cardiac tissue, a peak systolic pressure of 10
-12 mmHg and a strain of 8-15% were chosen for the whole experiment. To culture
cardiomyocytes under these conditions, a 500 μm thick membrane was selected and a
flow rate of ∼2.6 ml/min was used to attain a filling volume of 44 μl per cycle.

Following 24 h of culturing under static conditions to achieve 100% confluence, the cell
culture chamber with cells was transferred to the CCCM system and the system was
assembled as described in the section 4.3. The whole set-up CCCM system was then
moved into the cell culture incubator and was ready for mechanical stimulation for 4 days
at 37 °C and 5% CO2. The static pressure inside the cell culture chamber was reported
before the peristaltic pump was turned on. The flow rate was set at ~2.6 ml/min (~ 44
µl/cycle). The downstream one-way valve and the pressure from the generator were
adjusted to obtain cyclic pressures of 0-10 mmHg at a frequency of 2.0 Hz. Pressure
waveforms were checked in a period during 4 day stimulation. For comparison, the
control samples were cultured under a static condition in the same culture incubator with
the same amount of fresh culture medium.

After 4 days, the cell culture chamber was

removed from the CCCM platform and then maintained under a static condition for ∼3 h
prior to analysis.
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6.2.2.3. Results
During the CCCM stimulation, the instantaneous pressure generated inside the cell
chamber was obtained using a high fidelity pressure transducer and LabView software.
Based on the percentage of systolic versus diastolic timing set on the pressure generator,
along with the pressure waveform and fluid volume loaded to the chamber, the pressurevolume loop for a single working cycle of the CCCM was obtained (Fig. 6.2.).

c
d

b
a

a

Figure 6.2: Plot of pressure vs time and pressure-volume loop obtained within the
CCCM system. The changes in pressure within the CCCM cell culture chamber and
pressure−volume loop correlating changes in pressure with changes in volume within the
CCCM chamber was determined. The parameters of the pressure and fluid volume were
set up based on the parameters from the left ventricle of the embryonic chick heart.
Similar to the pressure-volume loop seen in the left ventricle of the heart, this pressurevolume loop represents the (a) filling phase, where the pressure was low but the volume
increased,

(b) the isovolumic contracting phase, where the pressure increases

significantly but the fluid volume was maintained the same during this phase, (c) the
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ejection phase, where the fluid was ejected out of the chamber, and (d) the isovolumic
relaxing phase where the pressure drop significantly with no change in the fluid volume.

After 4 days in the mechanical stimulations, the tissues were removed from the system,
followed by tissue analysis. Observed under the microscope, the stimulated construct has
more cardiac islands on the surface and looked more crowded and rougher, while the
control has a flatter surface with larger sized cells (Fig.6.3.).

Figure 6.3: Phase contrast images of in-vitro embryonic chick cardiac cells cultured
under the static and CCCM stimulated conditions. Left: embryonic chick cardiac cells
cultured under the static condition as a control. Right: embryonic chick cardiac cells
cultured under mechanical stimulations generated within the CCCM system. Compared
to the control cardiac tissue, the conditioned cells appeared to have higher cellular
density.
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6.2.3. Conclusion
The CCCM system is able to mimic the mechanical conditions which occur in the left
ventricle. Primary chick embryonic left ventricle cardiomyocytes are able to grow well
under the influence of cyclic mechanical stimulation generated within the CCCM system.
Further analysis between the stimulated and the static cultured groups will be described
below, included tissue alignment, beating rate, maturation, proliferation, and gene
expression.

6.3. CARDIAC TISSUE ALIGNMENT AND PROLIFERATION
6.3.1. Introduction
Cardiomyocytes continuously experience the stress and the change in length during the
heart cycle, due to the blood loading and unloading. Cardiac tissues are elongated during
diastolic phase and shortened during the systolic phase of a heart. These hemodynamic
stress and tissue strain affects cell proliferation and cytoskeletal remodeling.84 Indeed, in
response to the strain and stress, cardiomyocytes have the ability to remodel cell shape by
adding the sarcomere in series or filaments in parallel respectively to maintain cardiac
function.145 In addition, cardiomyocytes during embryogenesis have a high proliferation.
Staining nucleus with Bromodeoxyuridine (BrdU) along with DAPPI is a common
method to check the cell proliferation.

Proliferation =

100%
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6.3.2. Methods and materials
Immunofluorescence staining was used to evaluate the cell alignment and proliferation.
To examine the cell alignment, the constructs were stained with F-actin and α-actinin.
Before staining, the samples were fixed with 4% paraformaldehyde (PFA) at room
temperature (RT) for 20 min, followed by a washing with 1X phosphate buffered saline
(PBS) solution. A 0.1% Triton solution was then added to the constructs for 30 min, RT.
A solution of 0.5% BSA in 1X PBS was used as a blocking solution. For F-actin
staining, the samples were incubated with TRITC-conjugated Phaloidin (1:100;
Millipore, Billerica, MA) in the blocking solution for 1 h at RT. For α-actinin, primary
antibody cardiac α-actinin EA53 IgG1(1:400, Abcam, Ab7817) and second antibody antimouse (1:600, 488 green, Invitrogen, A21121) in 1% BSA/1X PBS

solution were

applied individually to the tissue for 1 h, RT, alternated with a washing buffer (0.05%
Tween-20/1X PBS) 1 h in between. DAPPI (1:100, Millipore, 90229) was also applied
to stain the nucleus at the end. Finally, the tissue constructs were mounted with anti-fade
solution (Invitrogen, San Jose, CA), and imaged using a Nikon A1 confocal microscopy
system (Nikon Instruments, 284 Melville, NY).

To examine cell proliferation, Bromodeoxyuridine (BrdU) incorporation during DNA
synthesis was utilized. Basically, 48 h prior to the tissues being fixed with PFA, 20 μM
of BrdU (Sigma) was added to the cell culture medium both for the control and the
stimulated tissues. After being removed from the present culture environment, the tissues
were fixed with 4% PFA solution for 20 min at RT and permeablized with 0.1% Triton
solution for 30 min at RT. A one hour washing with 1X PBS solution was performed
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before the HCl solution (1N) was added directly to the tissue on ice for 10 min. A 1N
HCl solution was then replaced by 2N HCl solution. After sitting at RT for 10 min, the
tissues in the 2N HCl solution were incubated at 37oC for an additional 20 min. A one
hour washing with 1X TBE buffer (10X TBE, Mediatech Inc., Manassas, VA, 46-011CM) at RT was performed before the tissues were blocked with a blocking solution (1%
BSA + 0.1% glycine in 1X PBS) for 1 h at RT. The tissues were then incubated with the
primary antibody Anti-BrdU (1:100, Abcam, ab1893) in the blocking solution for 24 h at
RT. After 1 h washing with the washing buffer, the tissue was incubated with secondary
antibodies, anti-sheep (1:400, red, Abcam, Ab6743) in the blocking buffer for 1 h at RT,
followed by another 1 h washing. DAPI (1:100, Millipore, 90229) was then added to
stain the nucleus at the end. Finally, the tissue constructs were mounted with anti-fade
solution (Invitrogen, San Jose, CA) and imaged using a Nikon A1 confocal microscopy
system (Nikon Instruments, 284 Melville, NY).

6.3.3. Results
Specimens were stained with F-actin and cardiac alpha-actinin antibodies, and then
examined under the confocal microscopy with 60X magnification. Compared to the
control group, embryonic chick heart cells in the CCCM tissue samples were more
aligned and oriented (Fig.6.4.). The parallel orientation showed up obviously in the
CCCM construct stained with F-actin. The cell arrangement of the control sample
appeared to be random.
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Figure.6.4: Immunofluorescence images of cardiomyocyte tissue cultured in the CCCM
system and in the static condition. (A) Images of the cell skeleton structure with f-actin
(green).

The stimulated tissue cultured in the CCCM system gave more parallel

arrangement compared to the random arrangement of the control tissues cultured under
the static condition (B) Images of cell alignment with α-sarcomeric actinin (red). The
picture of the CCCM construct shows in-vivo like matured tissues with stripped and
closer connection between cell-to-cell connections. The blue color is the nucleus stained
with DAPPI.

To determine the cell proliferation, BrdU, the marker stained for nuclei that have
synthesized new DNA during the BrdU treatment period, was used. Different locations
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of the constructs were observed under 60X magnification of the confocal microscope
(Fig.6.5.).

The dividing cells had nuclei that showed both blue and red colors

overlapping each other, while the undivided cells showed only blue nuclei. Red nuclei
without blue were the dead cells. The cell proliferation rate was determined by the ratio
between the dividing cells to the total of living cells. Six different experimental sets were
done for data statistical analysis.
[A]
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Figure 6.5: Results from immunofluorescence BrdU staining for cell proliferation. [A]
Immunofluorescence images of BrdU staining. Red: the nucleus stained with the BrdU
antibody; blue: nucleus stained with DAPPI. The dividing cells had both blue and red
nuclei; the undivided cells showed only blue nuclei; dead cells showed only red nuclei
without blue. [B] Graph of cell proliferation in controls and CCCM stimulated samples.
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The sample size was N = 6 with two tailed significance was set at ** p  0.05, meaning a
strong chance of having statistical significance between these 2 groups.

6.3.4. Discussions and conclusions
The alignment of cardiomyocytes and the cell proliferation were evaluated via immunefluorescence microscopy. Cardiomyocytes were subjected to mechanical stimulation.
Cell alignment expresses more in mature cells. Therefore, cardiomyocyte maturation was
observed under the immunofluorescence images via Phaloidin and sarcomeric α-actinin.
The result shows that the contraction-stretching of the cells promotes the increasing of Factin and helps to align the cells. Cell alignments demonstrated that mechanical loading
spontaneously rearranged the cytoskeletal orientation of the cells. In addition, from BrdU
staining, a higher proliferation rate was observed on the CCCM tissues rather than on the
control ones. This result suggests that applying mechanical stimulations on the embryonic
cardiac tissue is necessary to promote the cell alignment and proliferation rate of the
cardiomyocytes.

6.4. CARDIAC TISSUE MATURATION
6.4.1 Beat rate
Beat rates (BR) of the conditioned and control constructs were obtained after being
removed from the CCCM for 3 hours.

Two different time frames of the CCCM

stimulations (4 and 7 days in the CCCM system) were performed. At least 10 different
experiments on different dates were performed. The BR of the stimulated samples was
almost 1.5 times higher than the BR of control samples (Fig.6.6). In addition, the BR of
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the stimulated samples cultured in the CCCM system for 7 days yielded a little higher
than the BR of samples with 4 days stimulation, whereas the controls of both groups are
the same. This indicates that mechanical stimulations are important to maintain and
enhance the BR of the cardiac tissue.
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Figure 6.6: Graph of the beat rate (beats per min) between the control and the stimulated
groups. 2 different periods of mechanical stimulations (4 days and 7 days) were
performed along with their controls cultured under a static condition. Number of samples
was N=10. Two tailed significance was statically set at **p  0.005.

6.4.2. Electrical Pacing
Electrical pacing of stimulated constructs and unstimulated controls was accomplished to
identify changes in electrical properties in response to mechanical conditioning in the
CCCM. Platinum wire electrodes (d=0.5mm, Alfa Aesar, Ward Hill, MA, 43288) were
embedded vertically into the tissue-collagen gel matrix and connected to an electrical
pacing system (Isolated Programmable Stimulator, Colbourn Instruments, 02142-1) (Fig.
6.7).
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[A]

Figure 6.7:

[B]

Electrical Pacing Setup System.

[A] The image of the real pacing

experiment, which was set on the stage of the microscope before pacing the tissue. [B]
Diagram of the electrical stimulating, which was programed on the electrical pacing
system.

The maximum pacing tissue beat rate was recorded while varying the threshold voltage.
To find the maximum pacing rate, the voltage was increased from the lower to the higher
voltage until the BR reached to 2:1 phase (BR was half of the maximum BR). The
threshold voltage was also determined. This voltage was the voltage at which the tissue
started beating with the frequency of 2.0 Hz. The results show that the CCCM tissues
reached their maximum BR of 245bpm, which is close to the BR of the in-vivo mature
chick cardiac tissue (Fig. 6.8). In addition, the threshold voltage needed for the CCC
tissues to reach the frequency of 2.0 Hz was lower than the threshold voltage inserted on
the control samples. This result affirms that mechanical conditioning within the CCCM
resulted in tissue maturation represented by more efficient cell-cell connections and
higher maximal beat rates.
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Figure 6.8: Pacing Electrical Stimulation Results. [A] The Maximum Pacing Beat Rate
(bpm) between the non-stimulated (light blue) and the stimulated cardiac tissue group
(red). [B] The Threshold Voltage (V) in corresponding to the maximum pacing beat rate
for the non-stimulated and stimulated cardiac tissue groups.

N= 6 with two-tailed

significance set at ***P<0.05

6.4.3. Cell contractility
Movies of beating cardiomyocyte were recorded and analyzed to determine regional
tissue strain during contraction. For an individual sample, 5 different locations on the
movie were selected randomly for strain measurement. Lagrangian strain calculation for
finitely small displacement was used as previously described by Bonet et al.146 Briefly, if
p1 and p2 are two nearby points defined on the first frame, and d1 denotes the Euclidian
distance between p1 and p2 at the first frame (i.e., reference frame), then dj denotes the
Euclidian distance between these two points at time frame j, then, the engineering strain
S, at frame j, is defined as:
Sj = (dj-d1)/d1
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(8)

A custom algorithm was written to estimate the Lagrangian strain. First, the peak
displacement was determined by tracking two points based on their appearance features
through the image frames and calculating the displacement between the two points over
the image frames. The maximum displacement was then selected as the reference frame.
Then, five pairs of points on the first (reference) frame were determined and their tracked
pairs on the selected frame with maximum displacement. The Lagrangian strain for each
pair of points was estimated using equation (8). Finally, the mean Lagrangian strain was
calculated as expressed a % shortening.

The results show that without the electrical pacing, the percentage shortening of the
CCCM stimulated tissues was about 4.49 ± 0.88%, whereas controls were only at 2.73 ±
1.8% (Fig. 6.9). The unpaired t-test shows no statistical significance between the
shortening length of the control and the CCCM samples. However, when electrical
pacing was applied, the shortening of the CCCM stimulated tissues increased to 5.52 ±
0.88%, whereas the shortening of the un-stimulated tissue only went up to 2.96 ± 1.79%.
The statistical results showed significant difference with *p<0.05. These results suggest
that, the mechanical stimulation enhances the shortening of the cardiac tissue, and this
contractility increases further with the association of the electrical pacing applied on the
tissue.
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Figure 6.9: Graph of cardiomyocyte shortening with and without electrical stimulation:
control (black) and the CCCM stimulated (clear) samples evaluated with and without
electrical pacing. N=6 with two-tailed significance set at *P<0.05

6.5. CARDIAC TISSUE RESPONSE TO β-ADRENERGIC STIMULATION
6.5.1. Introduction
Isoproterenol (ISO) is a β-Adrenergic Agonist which binds to G-protein coupled βAdrenergic receptors (β-AR). The coupling of ISO/β-AR activates adenylyl cyclase
(AC). These activated AC catalyze the conversion of Adenosine triphosphate (ATP) into
cyclic adenosine monophosphate (cAMP), followed by the activation of protein kinase A
(PKA). After activated, PKA is able to phosphorylate L-type Ca2+ channel and
phospholamban (PLB); as a result, increase the Ca2+ influx into the cytosol and enhance
the activity of sarcoplasmic reticulum Ca2+ pump SERCA2a to transport Ca2+ from the
cytosol into the sarcoplasmic reticulum (SR).

Un-phosphorylated PLB inhibits the

activity of the SERCA2a pump. Phosphorylating of β-AR via PKA prevents the coupling
between ISO and β-AR and reduces the sensitization of β-AR to the agonist.54
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In

summary, ISO and β-AR play a significant role in the intracellular mediate signal
transduction pathway by enhancing the Ca2+ influx into SR and the transportation of Ca2+
from the cytosol into the SR, therefore, contributes to regulate the heart function via
contractility and frequency.

ISO affects the chick embryonic ventricle development as early as day 4th (out of a total
of 21 days of gestation before hatching) via the increase of contracting force of cardiac
tissue. In contrast to the mature heart, ISO does not affect the early embryonic heart until
the expression and coupling of functional β-AR. In addition to the positive chronotropic
and inotropic effects of ISO stimulation, ISO treatment also has a toxic effect on
developing and mature cardiomyocytes and can trigger cell death in cardiomyocytes from
a wide range of species.147-149 In adult hearts, ISO continues to enhance the rate of
tension development and beat rate (BR) of the tissues.150

Our hypothesis that, if

mechanical stimulation enhances the maturation of the cardiac tissue, in comparison to
the control tissue group, the contractility and the BR of the stimulated tissue group must
be increased in response to the ISO administration.

6.5.2. Material and Methods
Embryonic chick cardiac left ventricle cells at day 10 were isolated, seeded, and
experimented as mentioned in the previous sections. After being cultured for 4 days with
mechanical stimulation within the CCCM system, cardiac tissues were removed from the
system and incubated in a static condition at 37oC for another 3 hours before applying
ISO to the tissue. After 3 h, samples were brought to a microscope for analysis. Different
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concentrations of ISO (0.5µM, 1µM, 5µM, 10µM, and 50µM) (Sigma Aldrich, I6504) in
warmed fresh medium were applied respectively to the tissues. An electrical hot plate
was used to keep the temperature of the tissues and medium at 37oC. BR before and after
administrations were reported; and contractile movies were made within 5 minutes of
each ISO administration. Then, a brief washing with warmed fresh culture medium was
performed before adding a new higher dose of ISO to the tissue. Contractile movies were
analyzed using MATLAB software (MathWorks, Naticks, MA) to determine the
percentage shortening for tissue contractility.

6.5.3. Results
The effect of ISO on the BR and contraction of the constructs cultured in the
mechanically active CCCM system and in static conditions were observed. The BRs
before and after each ISO application were recorded. The BR of the tissue before the
0.5µM ISO solution added to the tissue was used as the referent BR to determine the
percentage change in BR under the effect of ISO administrations (Fig.6.10). The results
show that the BR of the CCCM group increased in response to increasing doses of ISO to
a maximal response at 10µM ISO, then declined. In contrast, the BR of the control group
decreased in response to increasing doses of ISO above 0.5µM. This result indicated that
the ISO produced a toxic response in static (unconditioned) chick cardiomyocytes.
However the CCCM stimulated group had positive chronotropic responses to ISO,
consistent with CM maturation.
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Figure 6.10: Plot represents the percentage change in beat rate of the cardiac tissue under
the effects of Isoproterenol.

While the control group showed cellular toxicity with

increasing ISO concentration, the beat rate of the stimulated group increased and reached
its peak at 10µM ISO. The horizontal line is the base line corresponding to the referent
beat rate recorded before the ISO applications. Five experiments were performed.

Cardiac contractility with and without ISO was also examined. Movies of each ISO
application were made and maximum contraction was chosen to determine tissue
shortening. Shortening was calculated as described in the section 6.4.3. With ISO
applications contractility of the stimulated tissues significantly increased versus the
unstimulated group, to 7.55 ± 0.78% versus 4.52 ± 0.43%, respectively (Fig. 6.11). In
response to ISO, contractility increased 67% in the conditioned group versus 36% in the
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unconditioned group.

These results suggest that mechanical stimulation may have

accelerated CM maturation as measured by reduced toxicity and increased BR and
shortening in response to ISO stimulation.
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Figure 6.11: Changes in the cardiomyocyte contraction with and without the influence
of ISO: controls (black) and CCCM stimulated (clear) constructs. Measurements were
made at 3 different locations on each sample. N= 6 different paired experimental sets.
Two tailed significance was set at ***p ≤ 0.001.

6.5.4. Discussion
Catecholamine affects mechanical performance of the heart tissues through the activation
of β-AR; and the cardiovascular function is controlled primarily on this adrenergic
signaling pathway.52-54 Under normal physiological conditions, catecholamine induces
positive inotropic and lusitropic responses in the heart tissue through β1-AR-activated
pathway. Once stimulation of β1-ARs via ISO binding occurs, cAMP accumulation
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rapidly increases which indirectly promotes the phosphorylation of PLB, and enhances
the cardiac contractility. Out of their subtypes, subtype β1-ARs exhibits dominantly
when cardiomyocytes become more mature under normal physiological condition.53, 56
This dominant β1-ARs, therefore, induces positive inotropy and lusitropy via heart rate
and contractility. Under the abnormal physiological condition of the heart, or failing
heart, β1-ARs decreases, but β2-ARs increases, causing cardiomyocyte death.56

After adding the ISO to the tissue, the CCCM conditioned constructs yielded a higher
percentage of contraction compared to the control ones; and the BR of the conditioned
tissue kept increasing until a 10 µM ISO solution (2.5mg/ml) was added. However, for
the controls, the concentration of ISO higher than 10µM created negative inotrope and
reduced BR on the cardiac tissue, and finally the cardiac tissue stopped beating This
result is similar to the result found in the early studies from Serverin,151 indicating that
these CM undergo cell damage and death if a higher concentration of ISO is applied.
These results state that, compared to the static cultured control group, the CCCM
stimulated construct has a higher response to the β-AR, and at the same time, has a higher
resistance against the cellular toxic effect of ISO, hence, is less likely to undergo cell
damage and death.

Higher response and higher resistance may be the result of higher

cell-cell connection, more maturity, or more population.

In conclusion, mechanical

stimulations of embryonic CM in the CCCM resulted in a more mature ISO response,
consistent with the maturation of β1-adrenergic signaling.

113

6.6. SELECTED CARDIOMYOCYTE GENE AND PROTEIN EXPRESSIONS IN
RESPONSE TO MECHANICAL CONDITIONING
6.6.1. Introduction
From previous results, embryonic chick cardiac tissues cultured in this CCCM system
showed a higher proliferation rate, better alignment, and more maturation via BR and
contractility. This section focusses on the effect of mechanical stimulation on proteins
that play a critical role in the beating rate and contractility of the heart tissue. Along with
the 2D constructs (CCCM stimulated and the control ones), ventricle tissues at day 16,
cell suspension from day 16th (same day harvesting the 2D constructs), and 3D
engineered cardiac tissues (ECT) harvested at culture day 5 (equivalent to day 16 chick
ventricular cells) were also collected for selected gene expression and protein synthesis
analysis.

As markers of CM maturation and function, sarcoplasmic reticulum calcium ATPase2a
(SERCA2a), phospholamban (PLN), Troponin T (TnT), and Alpha and Beta-Myosin
Heavy Chain (α-, β-MHC), and total protein were analyzed in control and conditions
tissues.

SERCA2a and PLB are essential proteins that regulate calcium cycling inside the
cardiomyocytes. These genes are involved in regulating the contraction-relaxation of the
heart muscle. Un-phosphorylated PLB binds to SERCA2a, prevents Ca2+ binding to
SERCA2a, and acts as an endogenous inhibitor of SERCA2a. Phosphorylated PLB
(pPLB) releases this inhibitory effect, making the affinity site to Ca2+ on SERCA2a more
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apparent. This activated SERCA2a then transports calcium against the gradient from
cytoplasm back to sarcoplasmic reticulum (SR).58 As the result, the rate of calcium ions
influx back to the SR increases, promoting the muscle relaxation prior to the next cycle of
calcium release and myofiber contraction.

Therefore, SERCA2a has a central role in

regulating Ca2+ cycling between the SR and myofibers and a direct impact on CM
contractility.

The regulation of SERCA2a activities plays a critical factor in the

contractile function and heart disease.152 32

TnT is the protein binding with tropomyosin and involved in the regulation of thin
filament function and the interaction between the thin and thick filament during myofiber
shortening.50 Abnormalities of this TnT gene are associated with sudden death in cardiac
patients. Myosin heavy chain (MHC) is the major sarcomeric protein expressed in heart
tissue during development and adulthood and regulates mechanical performance of the
heart, especially muscle contractility.64-66 Alpha and Beta MHC are the two important
isoforms of the MHC found in the heart tissue. β-MHC isoform is expressed mainly
during embryogenesis or heart diseases. α-MHC isoform exists dominantly in the adult
heart tissue and inhibits the expression of β-MHC. The ratio of α-MHC to β-MHC
expression is also seen in species with rapid or slow beating rates67

6.6.2. Methods
6.6.2.1. Cell suspensions and 3D ECT constructs
Cell suspension from ventricular cardiomyocyte tissues from day 16 were also isolated
using GentleMACS™ Dissociator (MACS Miltenyi Biotec, Auburn, CA), pre-plated, and
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rotated before being collected for cDNA and proteins. At the same time, ventricular
tissues from day 16 were also collected for cDNA and proteins.

To create 3D ECT constructs for PCR, the isolated embryonic cardiomyocyte clusters (~
3.0 x 104 clusters) were also mixed with collagen solution (0.667mg/ml) and seeded in
the TT-4001C Tissue Train™ plates (Flexcell® International Corporation, HillSborough,
NC) using Flexcell FX5X Tension system until the collagen solution was cured (about
1.5 h vacuumed, 37oC, 5% CO2) . Then the constructs were cultured under the static
condition for 5 days prior to analysis for PCR.

6.6.2.2. Real time PCR (qPCR) for gene expression
Total RNA was extracted from the cardiac constructs, cell suspensions, or ventricles,
using the Trizol isolation method. Briefly, the sample was homogenized in 1ml Trizol
three times (7 sec/each) in ice. After RNA isolation, cDNA was then transcribed via the
RNeasy mini kit (QIAGEN). The concentration of cDNA was measured using the
NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA). The real time
PCR for each target gene was then performed in triplicate. The GAPDH primer was
included as the housekeeping gene. SERCA2a, α and β MHC, TnT, and PLB were the
interested genes chosen for these PCRs. For data analysis, the relative quantification of
each target gene in each group was normalized to GAPDH. The fold change of each
interested gene was determined by ΔΔCt where the calibrating sample is the control
construct.
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6.6.2.3. Western blotting for protein synthesis
The end of the experiment, total protein of each sample was collected using the
Complete-Lysis M solution (Roche Diagnostics, Indianapolis, IN). The protein
concentration was then determined, using the NanoDrop 2000 Spectrophotometer. The
target proteins were separated using 10% SDS-PAGE and transferred to Immobilon™-FL
membranes (Millipore Corporation, Bedford, MA). After being blocked with 5% non-fat
milk, the membrane was probed with different primary antibodies including antiSERCA2a (1:500) (LSBio, Seattle, WA), anti α-MHC (1:150) (Santa Cruz, Dallas, TX)
and β-MHC (1:500) (Bioss, Woburn, MA), anti-Actinin (1:500) (Abcam, Cambridge,
MA), anti TnT (1:1000) (Sigma, St. Louis, MS) and anti β-actin (1:3000) (Cell Signaling,
Beverly, MA). The secondary antibody was Cy3®goat anti-Rabbit IgG (1:500) (Life
Technologies™, Grand Island, NY) and Cy5® goat anti-mouse IgG1 (1:500) (Abcam,
Cambridge, MA). The labeled bands representing the target proteins were visualized via
the Typhon 9400 system. NIH Image J software program was used for densitometry.

6.6.3. Results and discussions
6.6.3.1. Gene expression
Figure 6.12 and figure 6.13 show that compared to the level of gene expression in the
embryonic chick ventricle, gene expression decreased progressively from cells
suspension to 2D CCCM culture for all three genes: SERCA2a, α-MHC, and β-MHC.
The gene expression on 2D constructs, both the controls and the CCCM stimulated
samples, was much lower compared to the heart ventricles and cell suspension on day
16th, as was shown in a previous study.93 When compared, the 2D constructs together,
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gene expressions between the control and the CCCM group showed no significantly
statistic increase or decrease. The p values were greater than 0.05. However, gene
expressions of these genes were partially restored with the 3D ECT constructs especially
with PLN, α-MHC, and β-MHC genes .
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Figure 6.12: Plots of fold changes in gene expression with ventricular gene expression
set as the control state. [A] SERCA 2a gene expressions, [B] PLN gene expression. All
samples were collected on day 16th (out of 21 days of gestation). N ≥ 3 and p > 0.05.
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Figure 6.13: Plots of fold changes in gene expression with ventricular gene expression
set as the control state. [A] α-MHC gene expressions and [B] β-MHC gene expressions.
All samples were collected on day 16th (out of 21 days of gestation). N ≥ 3 and p > 0.05.

Figure 6.14 shows the total RNA synthesis obtained from 2D cardiac construct groups:
the control and the stimulated ones. From the plot, the embryonic chick cardiac tissues
stimulated yielded more RNA (1803 ± 218 ng/µl) than the tissues cultured under the
static condition (1186 ± 102 ng/µl); which was about 1.5 time higher.
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Figure 6.14: Total RNA obtained from 2D embryonic chick cardiac tissues. Total
samples N = 3, **p < 0.05

6.6.3.2. Protein Synthesis
More than 10 samples in pair (controls vs the CCCM stimulated groups) were used to
determine the total protein in each group. The total protein in the CCCD stimulated
constructs significantly increased (97.15 ± 4.97 mg) versus total protein in the 2D
controls (71.52 ± 4.14 mg) (Fig. 6.14)

Total protein (mg)

150

100

**
97.15
71.52

50

0

Controls

CCCM Stimulated

Figure 6.15: Total proteins of the 2D cardiac tissue constructs. N ≥ 12 two tailed
significance was set at ** p < 0.005.
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Five different CM proteins (SERCA2a, α- and β-MHC, α-Actinin, and TnT) were
selected for the Western Blot (Fig. 6.16). Figure 6.17 and figure 6.18 show the target
proteins collected from different conditions. Proteins SERCA2a, TnT, and β-MHC from
the cell suspension were much lower than those in the ventricular tissues. Interestingly,
the amount of α-Actinin protein almost doubled after cell isolation from ventricular
tissue. As noted in the previous study, protein levels decreased in response to 2D culture.
However, when mechanically conditioned in the CCCM system, protein levels were
modestly increased, except for myosin heavy chain proteins.

Figure 6.16: Images of Western Blot bands of the interested proteins in the 2D control
and CCCM stimulated groups
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Figure 6.17: Graphs of SERCA2a, α- and β-MHC proteins normalized by β-Actin. [A]
SERCA2a protein, [B] α-MHC protein, and [C] β-MHC protein. N ≥ 3 and two tailed
significance was set at *p < 0.05.
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Figure 6.18: Graphs of TnT and α-Actinin proteins normalized by β-Actin. [A] TnT
protein and [B] α-Actinin protein. N ≥ 3. SEM was used for error bars; and two tailed
significance was set at * p < 0.05 and **p<0.005.

6.6.4. Discussion
During cell isolation, cell-cell contacts are disrupted and extracellular matrix is
destroyed, causing cells to lose the extra cellular network connections that influence
many cellular functions, including calcium handling and contractility. Consistent with the
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negative impact of cell isolation is the disruption of gene expression and protein synthesis
of contractile relating proteins.93 As a result, gene expression and protein synthesis of the
Ca2+ regulating protein (SERCA2a) and contractile proteins (β-MHC) were lower in the
cell suspension group than in the ventricle group.

However, these results also

demonstrate that transcriptional and translational processes still occur and that viable
cardiomyocytes recover and mature in the CCCM. The protein α-MHC obtained from the
cell suspension was higher than those in the ventricular tissues, but was not statistically
significant. However, when these embryonic cardiac cells were cultured under 3D, gene
expressions of α-MHC, β-MHC, and PLN were augmented, demonstrating that 3D
culture is necessary for the cardiac tissue to fully regulate the transcriptional processes.
These results are similar to the results done by L.Khait and R.K.Birla group with neonatal
rat tissues.93 2D constructs are compacted, cells are laid on top of each other; therefore,
limiting their ability to arrange their orientation and their potentials to create their own
cellular matrix as well as to access their nutrients. 3D constructs allow cells more space
to rearrange their orientation, create their own cellular matrix, and build up their
connection among cells. Nutrients are easy to access. Therefore, when cells were
cultured under 3D condition, their gene expressions are nearly restored to levels found in
the 3D native ventricular tissues even though all these 3D ECT constructs in this
experiment were cultured under the static condition.

In contrast to other CM associated proteins, the protein synthesis of α-Actinin protein
doubled in the short time from ventricle tissue to cell suspension. The amount of Alphaactinin was also higher than those in the ventricular tissues. In cardiac cells, α-actinin
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protein is the cytoskeletal actin-binding protein to stabilize the contractile apparatus.42, 153,
154

Once the extra-cellular network was disrupted during the isolation, this protein

synthesis may be augmented due to the greater need in order to maintain the integrity of
cardiac function and stabilize the shape of the cells.

For 2D constructs, compared to the control unstimulated group, SERCA2a protein
synthesis in the stimulated tissue increased.

However, the result from gene expression

showed no statistically significant change in the SERCA2a gene expression including the
3D ECT constructs. In the cardiac cells, the sarcoplasmic reticulum where Ca2+ is stored
during the relaxing phase becomes functional only around birth and embryonic chick CM
are known to have immature SR;155 hence, it is understandable to show no significant
difference in SERCA gene expression. Further, the level of PLN in the CCCM tissues
was not significantly increased, compared to the static culture tissue, indicating that cells
did not undergo negative regulation in response to mechanical stimulation within the
CCCM system. In addition, the amount of total protein obtained from the conditioned
group was higher than the control one.

All these results affirm that mechanical

stimulation during embryogenesis mainly enhanced proliferation rate rather than increase
gene expression for SERCA.

Understanding these biomechanical responses of the

cardiac embryonic cells will be important for engineering myocardial tissue studies.

The two cardiac MHC isoforms reciprocally shift their expression depending on the
developmental stage and physiological condition of the heart. Before birth, β-MHC is the
main MHC isoform in the ventricle. After birth, β-MHC reduces dramatically but α-
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MHC increases significantly and becomes the main MHC isoform. The reversal of these
2 MHC isoforms is seen under heart failure diseases or in an aging heart in which βMHC is dominant. Our results showed no significant change of the α- and β-MHC gene
expression and the protein synthesis within 2D construct groups. First, no increase in the
β-MHC gene expression indicates that tissues undergoing mechanical treatment in the
CCCM system may become more mature and are not overstressed, which was supported
by the PLB gene expression level above. Second, this study was performed during the
embryonic and fetal stage, five days before hatching, indicating that the α-MHC
expression will not be dominant yet. Third, the expression of these isoforms is controlled
by thyroid hormone T3.64 Applying mechanical stimulation at an early stage of cardiac
tissue development may not be enough to promote α- and β-MHC gene expression, as
well as protein synthesis. In fact, the gene expressions and the reciprocity of these MHC
isoforms are controlled by developmental stages and thyroid hormone T3.

64, 156

Therefore, for further maturation of the tissue, besides mechanical conditions, the thyroid
hormone needs to be included to generate more MHC, especially when dealing with
embryonic cardiac tissue engineering for tissue transplant.

6.7. CONCLUSION
We have demonstrated that early mechanical stimulation during embryogenesis is needed
for tissue proliferation, maturation, responses to the β-adrenergic agonist, and protein
synthesis. Mechanical stimulations also help to maintain the calcium regulation inside the
cells. These results prove that CCCM system is a novel system to insert the in-vitro
mechanical stimulation on cardiac tissue; therefore, holds significant promise for
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generation of functional cardiac patches for replacement of injured cardiac tissue. 3-D
cell culture in CCCM with incorporation of thyroid hormone and mechanical stimulation
may be necessary for cardiac tissue engineering.
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CHAPTER 7
CONCLUSION

7.1. SUMMARY
CVD continues to be a major global healthcare dilemma. Current treatment options,
though beneficial, have significant limitations. In order to address these issues and
provide new treatment options, a better understanding of the molecular pathophysiology
of CVDs is necessary. Cellular level models provide the best platform for discovery
based studies. However, current approaches for cardiac cell culture fail to accurately
replicate the mechanical loading conditions seen in-vivo as a consequence of normal
hemodynamic loading and unloading. Available techniques address mechanical loading
on an individual basis, but to date, no system that accurately replicates the in-vivo
mechanical loading environment exists. This has resulted in cell-level studies being
conducted in environments with little or no physiological relevance.

The CCCM system was designed and developed to culture various cardiac cells in a
physiologically relevant environment by replicating the mechanical loading conditions
generated as a consequence of normal hemodynamic loading and unloading. Various
variables like cyclic pressure, strain and shear can accurately be replicated in a pulsatile
fashion similar to conditions experienced in the left ventricle of a heart. Characterization
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studies show that mechanical loading profiles associated with normal and various disease
conditions of the human heart, including heart failure, hypertension, hypotension,
bradycardia and tachycardia can be accurately replicated over extended periods of time.
Finally,

proof-of-concept

studies

using

primary

chick

embryonic

ventricle

cardiomyocytes confirms the ability of this system to generate in-vivo like mature cardiac
tissue cultured within this platform in phenotype, function and gene expression.

Thus far, characterization and proof-of-concept demonstrations were accomplished using
this CCCM system. Confirmation of the ability of the CCCM system to accurately
mimic the in-vivo cardiac environment allows for the design and study of various
conditions associated with CVD.

These future studies are likely to include

cardiomyocyte regeneration such as stem cells or adult cardiomyocyte regeneration using
a mechanical loading environment, study of cardiac and aortic endothelial cells under
conditions of continuous and pulsatile flow,114, 115 and finally evaluation of drugs and
other treatment options using cardiac cells maintained under various disease conditions.

7.2. LIMITATIONS
The CCCM system, however, has some limitations, including its complexity, the absence
of an authentic 3D cell culture, and lack of electrical and hormonal factors. First of all,
due to the complication of the system (tubes, valves, and multiple layers), it is time
consuming to set up one experiment which includes the cleaning, setting, and operating
processes. These can easily create a high risk of cross-contaminations. Second, ECM
was constructed before seeding the cells; once seeded, the cells attach well on the surface
of the ECM. Generated tissues hence cannot be easily detached from the crosslinking
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collagen matrix, which can create a serious issue for tissue transplant or tissue
regeneration. Thirdly, cardiomyocytes cultured in this system are in 2 dimensions on the
top of the gel matrix, not inside the matrix, therefore lack of a 3D ECM model, which
affects the development of the cardiac tissue including gene expression. Finally, beside
physiological and mechanical aspects, in-vivo cardiomyocytes are influenced by electrical
and hormonal stimulation. Mechanical, hormonal, and electrical aspects need to be
incorporated simultaneously for cardiomyocyte culturing.

7.3. FUTURE WORK
The CCCM system opens a wide opportunity to understanding the behavior of cardiac
cells on molecular and cellular levels. It also provides an excellent tool to regenerate
mature cardiac tissue for tissue transplant, which is our ultimate goal. From the previous
chapters, cardiac tissues cultured in the CCCM system become more mature via higher
beat rate, more alignment, and stronger contraction,. However, in this study, cardiac cells
were cultured on the surface of a soft collagen matrix and under mechanical stimulations
of a normal heart condition. For tissue regeneration or tissue transplant, it is necessary to
generate the 3D tissue without collagen matrix attached.

For molecular and cellular

studies, understanding the impact of mechanical stimulation for different cardiovascular
conditions on a heart tissue is crucial to provide a better treatment options for CVD. In
addition, with electrical pacing, the beating rate and the contraction increase significantly.
This electrical pacing for the in-vitro cardiac tissue can be considered as the sinoatrial
node in the heart, which generates impulses to the cardiac tissue at the greatest
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frequency.110 With these perspectives, the future works for this CCCM project might
include:
1. Using higher vertebrate (mammalian) tissues with 3D cell culture
Embryonic chick cardiac cells have been commonly used in studies. However, tissues
from higher mammal levels are more relevant to the human tissues. Also, cardiac tissue
is more physiologically relevant to the in-vivo cardiac tissue if it is cultured within a 3D
matrix. In addition, it is much better to use human iPS cell lines to study cardiac tissue
behavior and regenerate tissues. Similar to the Flexcell system, 3D cell culture can be
done in the cell culture chamber. In this case, the crosslinking matrix ring serves as an
anchor for the cell to attach and keep the tissue from forming a ball. Primary testing
results (not shown) proves that this technique can be used for cardiac culture under the
mechanical stimulation in the CCCM system and warrants further investigation.
2. Studies the effects of mechanical stimulations from various heart conditions
Chapter 5 shows that this CCCM system is capable of replicating different pathological
conditions.

Molecular and cellular studies of cardiac tissue under pathological

conditions can be specifically investigated.
3. Create a co-existing electrical and mechanical stimulation within the system.
Pilot studies with the CCCM system were conducted with simultaneous electrical and
mechanical stimulation.

The next step is to build a network for field electrical

stimulation inside the cell chamber. When mechanical stimulations causing the tissue to
go up and down, stretched and contracted, the electrical network must ensure that it won’t
create friction or tear the tissues apart.
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APPENDIX
LIST OF ABBREVIATIONS
Ao

Original cross-sectional area

AC

Adenyl cyclic

AR

Adrenergic Receptor

ATP

Adenosine triphosphate

BSA

Bovine Serum Albumin

BrdU

Bromodeoxyuridine

BR

Beat rate

cAMP

cyclic Adenosine Monophosphate

Ca2+

Calcium ion

CB

Cork Borer

CCCM

Cardiomyocyte Cell Culture Model

CM

Cardiomyocytes

CNC

Computer Numerical Control

cm

centimeter

CVD

Cardiovascular disease

d

Diameter

DI water

De-ionized water
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DMEM

Dulbecco’s Modified Eagles’s Medium

E

Young’s Modulus

ECM

Extra-cellular matrix

F

Tensile force

FBS

Fetal Bovine Serum

FEA

Finite Element Analysis

h

Height

HF

Heart Failure

HH

Hamburger Hamilton

ID

Inner diameter

ISO

Isoproterenol

l, L

Length

Lo

Original length of the membrane

LV

Left ventricle

LVAD

Left ventricle assistant device

L0

Length between two black dots at 0.0 mmHg

Lf

Length between two black dots after pressure is applied

MHC

Myosin Heavy Chain

mL

Milliliter

mm

Millimeter

N

Total number of the sample

OD

Outer diameter

PBS

Phosphate Buffer Saline

146

PDMS

Polydimethyl siloxane

PFA

Paraformaladehyde

PKA

Protein Kinase A

PLB, PLN

Phospholamban

pPLB, pPLN

Phosphorylated phospholamban

R

Radius

Rf

Final radius

Ri

Initial radius

RIE

Reactive Ion Etcher

rpm

revolution per minute

RT

Room Temperature

SERCA2a

Sarcoplasmic reticulum calcium ATPase 2a

SR

Sarcoplasmic reticulum

TnT

Troponin T

V

Volume

σ

Engineering stress

σ*

True stress

ε

Engineering strain

ε*

True strain

εr

Radial strain

εc

Circumferential strain

λc

Circumferential stretch ratio

τ
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µ
µCCCM
µL

Shear stress
Viscosity
Microfluidic cardiac cell culture model
Microliter
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